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Abstract
Plasmodium falciparum and Plasmodium vivax cause the majority of human malaria cases.
Research efforts predominantly focus on P. falciparum because of the clinical severity of
infection and associated mortality rates. However, P. vivax malaria affects more people in a
wider global range. Furthermore, unlike P. falciparum, P. vivax can persist in the liver as
dormant hypnozoites that can be activated weeks to years after primary infection, causing
relapse of symptomatic blood stages. This feature makes P. vivax unique and difficult to
eliminate with the standard tools of vector control and treatment of symptomatic blood stage
infection with antimalarial drugs. Infection by Plasmodium is initiated by the mosquito-trans-
mitted sporozoite stage, a highly motile invasive cell that targets hepatocytes in the liver.
The most advanced malaria vaccine for P. falciparum (RTS,S, a subunit vaccine containing
of a portion of the major sporozoite surface protein) conferred limited protection in Phase III
trials, falling short of WHO-established vaccine efficacy goals. However, blocking the sporo-
zoite stage of infection in P. vivax, before the establishment of the chronic liver infection,
might be an effective malaria vaccine strategy to reduce the occurrence of relapsing blood
stages. It is also thought that a multivalent vaccine comprising multiple sporozoite surface
antigens will provide better protection, but a comprehensive analysis of proteins in P.
vivax sporozoites is not available. To inform sporozoite-based vaccine development, we
employed mass spectrometry-based proteomics to identify nearly 2,000 proteins present in
P. vivax salivary gland sporozoites. Analysis of protein post-translational modifications
revealed extensive phosphorylation of glideosome proteins as well as regulators of tran-
scription and translation. Additionally, the sporozoite surface proteins CSP and TRAP,
which were recently discovered to be glycosylated in P. falciparum salivary gland
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sporozoites, were also observed to be similarly modified in P. vivax sporozoites. Quantita-
tive comparison of the P. vivax and P. falciparum salivary gland sporozoite proteomes
revealed a high degree of similarity in protein expression levels, including among invasion-
related proteins. Nevertheless, orthologs with significantly different expression levels
between the two species could be identified, as well as highly abundant, species-specific
proteins with no known orthologs. Finally, we employed chemical labeling of live sporozoites
to isolate and identify 36 proteins that are putatively surface-exposed on P. vivax salivary
gland sporozoites. In addition to identifying conserved sporozoite surface proteins identified
by similar analyses of other Plasmodium species, our analysis identified several as-yet
uncharacterized proteins, including a putative 6-Cys protein with no known ortholog in P.
falciparum.
Author summary
Malaria is one of the most important infectious diseases in the world with hundreds of
millions of new cases every year. Malaria is caused by parasites of the genus Plasmodium
which have a complex life cycle, alternating between mosquito and mammalian hosts.
Human infections are initiated with a sporozoite inoculum deposited into the skin by par-
asite-infected mosquitoes as they probe for blood. Sporozoites must locate blood vessels
and enter the circulation to reach the liver where they invade and grow in hepatocytes. In
the case of Plasmodium vivax, one of the two Plasmodium species responsible for the
majority of the disease burden in the world, the parasite has the ability to persist for
months in the liver after the initial infection and its activation causes the recurring appear-
ance of the parasite in the blood. Though all clinical symptoms are attributable to the
blood stages, it is only by attacking the transmission stages before the formation of hypno-
zoites (the persisting parasites in the liver) that an impact on the burden of vivax malaria
can be achieved. We used state-of-the-art mass spectrometry-based proteomics tools to
identify the total protein make-up of P. vivax sporozoites. By analyzing which proteins are
exposed to the parasite surface and determining the degree of protein’s post-translational
modifications, our investigation will aid the understanding of the novel biology of sporo-
zoites and importantly, advise the development of potential vaccine candidates targeting
this parasite stage.
Introduction
Malaria is a major global infectious disease, responsible for nearly 429,000 deaths and 212 mil-
lion new cases annually (World Malaria Report 2016, WHO). This disease, found in much of
the tropical and subtropical regions of the world, is caused by parasites of the genus Plasmo-
dium, transmitted to humans by the bite of infected anopheline mosquitoes. Parasites (sporo-
zoites) that have infected the mosquito salivary gland are transmitted to the human host as the
mosquito injects saliva while taking a blood meal. These sporozoites find their way to the liver
where they invade hepatocytes and reproduce asexually. The mature liver stages rupture and
the release of exoerythrocytic merozoites that are ready to invade erythrocytes causes the clini-
cal symptoms of malaria.
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The majority of human malaria cases are caused by P. falciparum and P. vivax. A large pro-
portion of malaria research efforts focus on P. falciparum infections, motivated by the severity
of clinical symptoms and the high mortality rate that is especially evident among children in
sub-Saharan Africa. In contrast, P. vivaxmalaria affects more people in a wider global range
[1, 2], but infections with P. vivax often do not cause disease that matches the severity observed
for P. falciparum infections. P. vivax-infected individuals of all age groups may still endure
repeated, debilitating febrile attacks, severe anemia, and respiratory distress that are more fre-
quently fatal than previously appreciated [3]. Additionally, with only one exposure to infec-
tious mosquito bite, P. vivax can initiate not only one symptomatic infection but a series of
reoccurring onsets of malaria episodes that, if not treated, can last for months. These recurring
infections are due to a distinctive property of P. vivax liver infection: formation of hypnozoites,
a portion of P. vivax liver-stage parasites that becomes dormant and can reactivate weeks to
months or even years later [4].
The malaria elimination strategies of vector control and treating symptomatic blood-stage
infection with anti-malarial drugs are not as effective against P. vivax as against P. falciparum
because P. vivax can persist in the liver as dormant hypnozoites, and because P. vivax gameto-
cytes develop earlier and can be transmitted before onset of clinical symptoms [5–7]. Cur-
rently, the only approved treatment for P. vivax is primaquine. Primaquine, however, comes
with major complications: its short half-life translates to long dosage regimens, its toxicity for
patients with glucose-6-phosphate-dehydrogenase deficiency requires pre-screening of recipi-
ents [8], and limited effectiveness in patients with certain cytochrome P450 2D6 polymor-
phisms will require consideration [9].
An alternative route to reducing the burden of vivax malaria would be the development of
an effective vaccine against P. vivax. Targeting P. vivax pre-erythrocytic stages (the sporozoite
stage and the liver stage) for vaccine development not only has the advantage that these initial
stages of infection involve only a small number of parasites and are completely asymptomatic,
but also that such a vaccine could prevent relapsing infections. In fact, one of the most effective
experimental vaccination strategies against P. falciparum infection is the use of live attenuated
sporozoites (damaged by irradiation) that are effective in inducing complete immune protec-
tion by their ability to mount humoral and cellular immune responses against the sporozoite
and the liver stage of the parasite [10]. This method of vaccination was recently tested in P.
vivax showing encouraging protective efficacy [11]. Nevertheless, the major obstacle for a suc-
cessful pre-erythrocytic vaccine lies in the required threshold for vaccine efficacy: to protect
against infection, the pre-erythrocytic vaccine must be completely effective. Full development
of a single liver-stage parasite and exoerythrocytic merozoite release results in full-blown
blood stage infection and all the clinical consequences of the disease. This requirement–induc-
ing sterile immunity by targeting the liver stages–may be especially difficult to achieve for vac-
cines targeting the liver stages of P. vivax due to the ability of the parasite to form hypnozoites.
It is presently unknown if vaccination regimens that target developing liver stages would also
be able to target hepatocytes harboring hypnozoites.
Thus, an effective subunit vaccination strategy that targets the parasite before it enters the
hepatocyte could be the most plausible solution for preventing a P. vivax hepatocyte infection,
development of liver-stage parasites, and hypnozoite formation. It has been shown that anti-
body responses against the circumsporozoite protein (CSP), a major surface protein on the
Plasmodium sporozoite, can lead to sterile protection against infection, but in most cases these
responses offer only partial protection in P. falciparum [12]. A recent clinical study in which a
P. vivaxCSP-based subunit vaccine was used showed no sterile protection, but a significant
delay in the onset of parasitemia was observed [13]. As opposed to P. falciparum infection
where partial protection offers only limited benefits, partial protection that could be observed
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after immunizations against P. vivax has the potential to considerably affect the hypnozoite
burden in the liver by limiting the number of sporozoites reaching the hepatocyte and develop-
ing into hypnozoites, thereby directly decreasing the chances of relapse malaria [14]. A vaccine
targeting P. vivax sporozoites is therefore highly desirable.
The identification of non-CSP antigens that can be included into a multi-antigen subunit
vaccine has recently gained momentum for P. falciparum, but such an effort has not yet been
initiated for P. vivax. After mosquito transmission, sporozoites embark on a complex route of
infection in the human host and three biological activities of the sporozoite are essential for
their success, namely, gliding motility, cell traversal, and cell invasion. All of these activities
require engagement of sporozoite surface and secreted proteins with the host environment
and thus might be blocked by antibodies. Therefore, the discovery of new P. vivax sporozoite
surface antigens, together with CSP-based antigens, may allow the development of a better
antibody-based, anti-infection vaccine [15].
Mass spectrometry (MS)-based proteomics has previously been employed to catalogue the
protein complement of P. falciparum, P. yoelii and P. berghei salivary gland sporozoites with
the goal of identifying new targets for therapeutics and new antigens for subunit-based vac-
cines [16–20]. The most comprehensive proteomic analyses to-date of P. falciparum salivary
gland sporozoites detected over 2000 of the approximately 5000 gene products predicted from
the Plasmodium falciparum genome [19] and identified 42 putatively surface-exposed sporozo-
ite proteins [20] by a chemical labeling strategy. Here, by applying similar proteomics tech-
niques to the analysis of the proteins present in P. vivax salivary gland sporozoites of field
isolates, a combined total of 1970 P. vivax proteins were identified, of which 36 have been cate-
gorized as putative sporozoite surface proteins. Post-translational modification of sporozoite
proteins by glycosylation and phosphorylation have also been evaluated to further aid the
development of subunit vaccines.
Materials and methods
Ethics statement
The human blood collection protocol was approved by the Ethical Committee of the Faculty of
Tropical Medicine, Mahidol University. All adult subjects participating in this study provided
written informed consent. No child participants were included in this study.
Production of Plasmodium vivax sporozoite-infected mosquitoes
Anopheles dirusmosquitoes (from the Mahidol University colony maintained at the Faculty of
Tropical Medicine laboratories) were infected with blood collected from patients who were
confirmed positive for only P. vivaxmalaria via microscopy at local health centers in close
proximity to the Kanchanaburi Campus, Mahidol University. In brief, 150 μL of red blood cell
pellet from blood samples was suspended in pooled normal AB serum to a packed cell volume
of 50%. The suspension was fed for 30 min to 100 female mosquitoes (5-7 days old) via an arti-
ficial membrane attached to a water-jacketed glass feeder maintained at 37˚C. Unfed mosqui-
toes were removed and fed mosquitoes were maintained on a 10% w/v sucrose solution and
incubated at 26˚C and 80% humidity for at least 14 days. Salivary gland dissections were per-
formed at days 14-19. CSP haplotype (VK210 or VK247) was determined by PCR.
Sporozoite isolation, purification and surface labeling
Salivary glands from P. vivax-infected mosquitoes were harvested by microdissection and
homogenized by grinding. Sporozoite preparations were purified from mosquito debris on an
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Accudenz discontinuous gradient as previously described [21]. Total sporozoite numbers were
counted on a hemocytometer. For the total proteome analyses, 3.5 × 106 VK210 and 4.5 × 106
VK247 sporozoites were pelleted for 3 min at 16,000 × g, re-suspended in 1 × PBS pH 7.4, pel-
leted, and stored at -80˚C. Prior to protein separation by SDS-PAGE, the pellet was re-sus-
pended in an equal volume of 2 × sample buffer and heated for 5 min at 70˚C. For the surface
proteome samples, 2 × 106 VK210 and 1.8 × 107 VK247 sporozoites were pelleted for 3 min
at 4,000 × g at 4˚C and re-suspended with ice-cold 1 × PBS pH 8.0. The VK247 sample was
evenly split into two tubes and all three samples were pelleted again. One of the VK247 samples
was set aside as an unlabeled control. The remaining two samples were re-suspended in
40 μL ice-cold 1 × PBS pH 8.0 per 106 sporozoites. A 10 mM stock solution of EZ-Link Sulfo-
NHS-SS-Biotin (Thermo Fisher Scientific, part number 21331) was added to a final concentra-
tion of 2 mM and the samples were incubated for 1 h at 4˚C. The sporozoites were pelleted
and re-suspended in 500 μL ice-cold 1 × Tris-buffered saline (TBS) pH 8.0 and incubated for 5
min on ice to quench excess biotin label. The sporozoites were then pelleted for 2 min at
16,000 × g and washed a second time in 1 × TBS, each time removing as much supernatant as
possible without disturbing the pellet. The samples were stored at -80˚C until lysis. The sporo-
zoites were lysed by re-suspending the pellet in 100 μL lysis buffer (1% w/v SDS, 4 M urea, 50
mM Tris-HCl pH 8.0, 150 mM NaCl, 1 × protease inhibitor (Roche cOmplete)) and incubating
for 30 min at 4˚C with end-over-end rotation. The samples were diluted to 1 mL in 1 × PBS
pH 7.4, added to 1 mg of magnetic streptavidin beads (Dynabeads MyONe Streptavidin T1)
which had been washed three times in 1 × PBS, and incubated for 1 h at 4˚C with end-over-
end rotation. The beads were washed sequentially with the following: 1) 2% w/v SDS; 2) 0.1%
w/v SDS, 6 M urea, 1 M NaCl, 50 mM Tris-HCl pH 8.0; 3) 0.1% w/v SDS, 4 M urea, 200 mM
NaCl, 1 mM EDTA, 50 mM Tris-HCl pH 8.0; 4) 0.1% w/v SDS, 50 mM NaCl, 50 mM Tris-
HCl pH 8.0. Bound proteins were eluted by adding 40 μL 2 × sample buffer (4% w/v SDS, 125
mM Tris-HCl pH 6.8, 20% v/v glycerol, 0.02% w/v bromophenol blue) to which dithiothreitol
(DTT) was added to a final concentration of 50 mM and heating the tube for 7 min at 70˚C.
The eluted sample was transferred to a new tube and stored at -80˚C until separation by
SDS-PAGE.
SDS-PAGE fractionation
SDS-PAGE pre-fractionation and in-gel tryptic digestion were performed essentially as
described in [19]. Extended methods are provided in S1 File. Briefly, samples were electropho-
resed through a 4-20% w/v SDS-polyacrylamide gel (Pierce Precise Tris-HEPES). Gels were
stained with Imperial Stain (Thermo Fisher Scientific), de-stained in Milli-Q Water (Milli-
pore), and cut into fractions (S1 Table). Gel pieces were then de-stained with 50 mM ammo-
nium bicarbonate (ABC) in 50% acetonitrile (ACN) and dehydrated with ACN. Disulfide
bonds were reduced with 10 mM DTT and cysteines were alkylated with 50 mM iodoaceta-
mide in 100 mM ABC. Gel pieces were washed with ABC in 50% ACN, dehydrated with ACN,
and rehydrated with 6.25 ng/μL sequencing grade trypsin (Promega). The supernatant was
recovered and peptides were extracted by incubating the gel pieces with 2% v/v ACN/1% v/v
formic acid, then ACN. The extractions were combined with the digest supernatant, evapo-
rated to dryness in a rotary vacuum, and reconstituted in liquid chromatography (LC) loading
buffer consisting of 2% v/v ACN/0.2% v/v trifluoroacetic acid (TFA).
Liquid chromatography-mass spectrometry
LC and MS parameters were essentially as described previously [19, 20]. Extended method
details are provided in S1 Table. Briefly, LC was performed using an Agilent 1100 nano pump
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with electronically controlled split flow or a Proxeon Easy nLC. Peptides were separated on a
column with an integrated fritted tip (360 μm outer diameter (O.D.), 75 μm inner diameter
(I.D.), 15 μm I.D. tip; New Objective) packed in-house with a 20 cm bed of C18 (Dr. Maisch
ReproSil-Pur C18-AQ, 120 Å, 3 μm). Prior to each run, sample was loaded onto a trap column
consisting of a fritted capillary (360 μm O.D., 150 μm I.D.) packed with a 1 cm bed of the same
stationary phase and washed with loading buffer or buffer A (0.1% v/v formic in water). The
trap was then placed in-line with the separation column for the separation gradient. The LC
mobile phases consisted of buffer A and buffer B (0.1% v/v formic acid in ACN). The separa-
tion gradient was 5% B to 35% B over 60 min for the surface-labeled samples and 5% B to 25%
B over 120 or 180 min for the whole proteome samples. Tandem MS (MS/MS) was performed
with an LTQ Velos Pro-Orbitrap Elite (Thermo Fisher Scientific). Data-dependent acquisition
was employed to select the top precursors for collision-induced dissociation (CID) and analy-
sis in the ion trap. Dynamic exclusion and precursor charge state selection were employed.
Two nanoLC-MS technical replicates were performed for each fraction, with roughly half the
available sample injected for each replicate.
Peak list generation
The MS data generated for this manuscript, along with the search parameters, analysis parame-
ters and protein databases can be downloaded from PeptideAtlas (www.peptideatlas.org)
using the identifiers PASS00976 (whole proteome) and PASS00977 (surface-labeled). Mass
spectrometer output files were converted to mzML format using msConvert version 2.2.0
(whole proteome data) or 3.0.5533 (surface-labeled data) [22] and searched with Comet ver-
sion 2015.02 rev.0 [23]. The protein sequence database is described in the following section.
The precursor mass tolerance was ±10 ppm, and fragment ions bins were set to a tolerance of
1.0005 m/z and a monoisotopic mass offset of 0.4m/z. Semi-tryptic peptides and up to 2
missed cleavages were allowed. The search parameters included a static modification of
+57.021464 Da at Cys for formation of S-carboxamidomethyl-Cys by iodoacetamide and
potential modifications of +15.994915 Da at Met for oxidation, -17.026549 Da at peptide N-
terminal Gln for deamidation from formation of pyroGlu, -18.010565 Da at peptide N-termi-
nal Glu for loss of water from formation of pyroGlu, -17.026549 Da at peptide N-terminal Cys
for deamidation from formation of cyclized N-terminal S-carboxamidomethyl-Cys, and
+42.010565 for acetylation at the N-terminus of the protein, either at N-terminal Met or the
N-terminal residue after cleavage of N-terminal Met. Additionally, the search parameters for
sporozoite surface samples included a potential modification of +145.019749 Da at Lys for
addition of the biotin label, the disulfide bond of which had been cleaved and alkylated. The
MS/MS data were analyzed using the Trans-Proteomic Pipeline (TPP) [24] version 5.0.0
Typhoon. Peptide spectrum matches (PSMs) were assigned scores in PeptideProphet [25],
peptide-level scores were assigned in iProphet [26], and Protein identifications were inferred
with ProteinProphet [27]. Additional TPP parameters are available in S1 File. In the case that
multiple proteins were inferred at equal confidence by a set of peptides, the inference was
counted as a single identification and all relevant protein IDs were listed. Only proteins with
ProteinProphet probabilities corresponding to a false discovery rate (FDR) less than 1.0% (as
determined from the ProteinProphet mixture models) were reported. For comparison with P.
falciparum salivary gland sporozoites, a publically available data set [19] (available from Pepti-
deAtlas using the identifier PASS00095) was re-analyzed with the same software and parame-
ters described above. The spectra were searched against a database comprising P. falciparum
3D7 [28] (PlasmoDB v.30, www.plasmodb.org [29]), Anopheles stephensi Indian AsteI2.3 [30]
(VectorBase, www.vectorbase.org [31]), and a modified version of the common Repository of
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Adventitious Proteins (v.2012.01.01, The Global Proteome Machine, www.thegpm.org/cRAP)
with the Sigma Universal Standard Proteins removed and the LC calibration standard peptide
[Glu-1] fibrinopeptide B appended. Decoy proteins with the residues between tryptic residues
randomly shuffled were generated using a tool included in the TPP and interleaved among the
real entries. P. falciparum protein annotations were updated from PlasmoDB v.32.
Compiling a reference proteome
A protein database containing sequence polymorphisms of P. vivax proteins occurring in
Thailand was created by aligning DNA-seq and RNA-seq reads from field isolates to the P.
vivax Sal-1 genome [32] (PlasmoDB v.26). DNA-seq reads from 19 Thai field isolates were
obtained from www.plasmodb.org and aligned using Burrows Wheeler Aligner (v.0.7.12)
and SNVs were called using the Genome Analysis Toolkit (v.3.6). RNA-seq reads for 13 iso-
lates [33] (obtained from https://www.ncbi.nlm.nih.gov/bioproject/, accession number
PRJNA376620) were aligned using STAR (v.2.5) and SNVs were called using the Genome
Analysis Toolkit (v.3.6). All proteins with sequences different from the Sal-1 reference prote-
ome were compiled (S2 File) and added to a database comprising P. vivax Sal-1 [32] (Plas-
moDB v.31), P. vivax P01 [34] (PlasmoDB v.31), Anopheles stephensi Indian AsteI2.3 [30]
(VectorBase), and the modified version of the cRAP proteins described above. Decoy proteins
were generated as above. Mass spectra from the two whole-proteome samples and the two sur-
face-labeled samples were searched against the database with Comet as described above and
the resulting PSMs were analyzed with PeptideProphet and iProphet as described above except
that the NSP model was enabled in iProphet. All P. vivax peptides identified with iProphet
probabilities corresponding to a model-estimated FDR less than 1.0% were aligned against the
P. vivax P01 reference proteome. A new P. vivax P01 reference proteome was assembled incor-
porating polymorphism-bearing peptides identified by the above-described search. If a
detected peptide was associated with a given P. vivax protein in at least one of the field
isolates but did not align with the P. vivax P01 reference sequence due to sequence polymor-
phisms, the variant peptide sequence was appended to the end of the reference protein
sequence entry in the fasta database. This modified P. vivax P01 reference proteome was added
to the An. stephensi and cRAP databases described above. Additionally, the entry for CSP
(PVP01_0835600), which contains the tandem repeat region specific to the VK210 haplotype,
was appended with the sequence of the VK247 tandem repeat region [35]. Decoys were gener-
ated as above. This database was used for all subsequent analysis of the MS data. P. vivax pro-
tein annotations were updated from PlasmoDB v.32.
Protein quantification
Relative protein abundance within and between samples was estimated using a label-free pro-
teomics method based on spectral counting. Extended method details are provided in S1 File.
The spectral counts for a protein were taken as the total number of high-quality PSMs (identi-
fied at a PeptideProphet probability corresponding to an FDR less than 1.0%) that identified
the protein. PSMs from degenerate peptides (peptides whose sequences were found in multiple
proteins in the database) were split among proteins containing that peptide in a weighted fash-
ion [36, 37]. Relative protein abundance within samples was ranked using the normalized
spectral abundance factor. The spectral abundance factor (SAF) for a given protein was calcu-
lated as the quotient of the total PSMs identifying that protein and the protein’s length. The
SAF for each Plasmodium protein was normalized to the sum of all Plasmodium SAF values
obtained from the same sample, and this normalized SAF (NSAF) was natural log-transformed
to ln(NSAF) [38, 39]. The population of ln(NSAF) values for each sample assumed a normal
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distribution, as did the population of log-transformed protein abundance fold-change ratios
between samples, calculated as ln(NSAF)A-ln(NSAF)B where A and B are two different sam-
ples in which the same protein was observed. Each of these distributions was fit with a Gauss-
ian curve in Microsoft Excel using minimum residual sum of squares and goodness-of-fit was
evaluated with the R2 coefficient of determination (S1 and S2 Figs). To assess the relative abun-
dance of proteins between the two samples, PSM counts for all proteins were first increased by
1 in order to assign non-zero values to proteins detected in one sample but not the other [40].
These adjusted spectral counts were then normalized so that the sum of all PSMs was the same





Where RA:B is the protein abundance ratio of a protein between sample A and sample B and cA
and cB are the adjusted and normalized spectral counts for the protein in sample A and sample
B, respectively. In order to assess the error in spuriously large protein ratios obtained from
proteins with low spectral counts, the G-test of significance was applied to the adjusted and
normalized spectral counts for each protein pair as












and a p-value was assigned by calculating the probability that a χ2 distribution with one degree
of freedom was more extreme than the G statistic [40]. The distribution of the log2(RA:B) values
of all proteins detected in both samples was fit with a Gaussian curve as above. Protein abun-
dance ratios were corrected for systematic bias by subtracting the mean of this distribution
(which was near 0 in all cases) from each log-transformed protein ratio. In order to assess the
probability that a protein ratio was more extreme than the normal distribution of protein















where μ is the mean and σ is the standard deviation of the fit Gaussian. The FDR arising from
multiple hypothesis testing was assessed by the Benjamini-Hochberg method for both tests
independently, and protein ratios with an FDR less than 5.0% by both the G-test and ERFC
were considered significant.
Identifying phosphorylated proteins
Phosphorylated peptides were identified by searching the MS data with the same parameters
listed above with the additional potential modification mass of +79.966331 Da at Ser, Thr, and
Tyr. The PSMs generated from these searches were analyzed separately by PeptideProphet as
above, except that the DECOYPROBS option was used so that decoy peptides were assigned
probabilities and included in the output. Decoy peptides were used to calculate an FDR among
the subset of PSMs exhibiting phosphorylation. Due to the infrequent occurrence of phospho-
peptides in these un-enriched samples, the decoy-estimated FDR for phosphopeptide PSMs
was as high as 24% in the VK210 sample and 19% in the VK247 sample at the probabilities cor-
responding to a 1.0% decoy-estimated FDR for the entire population of PSMs. The more strin-
gent cut-off to achieve 1.0% FDR among phosphopeptide PSMs was used to identify high-
confidence phosphopeptides. Phosphopeptide PSMs within each sample were only counted if
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the phosphopeptide was identified by at least one PSM at the high-stringency cut-off and by at
least two PSMs in the population-level cut-off. The number of PSMs identifying a phospho-
peptide and the number of PSMs identifying the same peptide in un-phosphorylated form
were used to estimate the percentage of that peptide that was phosphorylated in the sample.
Localization of phosphate groups within phosphopeptides was confirmed and/or corrected
using a development version of PTMProphet (source code available at https://sourceforge.net/
p/sashimi, SVN revision number 7584. See S1 File for complete parameters).
Prioritizing proteins identified from surface labeling
Experimental and theoretical evidence was used to identify high-confidence putatively sur-
face-exposed proteins from among those P. vivax proteins identified by surface labeling live
sporozoites with the biotin tag. Proteins were taken for further consideration if they were iden-
tified by at least two peptides and three PSMs in at least one of the two labeled samples. Pro-
teins were considered high-quality candidates if they possessed predicted characteristics of a
surface protein, i.e., transmembrane (TM) domain(s), a signal peptide, or a glycophosphatidy-
linositol (GPI) anchor, or if they exhibited spectral evidence for incorporation of the biotin
label. Theoretical evidence for presence of surface protein characteristics was determined from
protein primary sequences using established tools: the number of predicted TM domains was
obtained from THMM2 [41] via PlasmoDB.org (P. vivax P01 v.31), presence of a signal pep-
tide was predicted by SignalP version 4.1 [42] (http://www.cbs.dtu.dk/services/SignalP/) and
presence of a glycosylphosphatidylinositol (GPI) anchor was predicted using PredGPI [43]
(http://gpcr2.biocomp.unibo.it/gpipe/index.htm). A protein was considered to have spectral
evidence for labeling if a non-degenerate component peptide displaying the addition of the
biotin tag was identified from at least one high-quality PSM (PeptideProphet probability corre-
sponding to an FDR less than 1.0%). Non-specific binding to the streptavidin beads was
assessed by comparing the VK247 labeled and unlabeled samples, which were split from the
same sample and processed in parallel with or without labeling. In order to identify those pro-
teins with the highest value as potentially surface-exposed targets based on the theoretical and
experimental evidence, proteins were assigned priority tiers (1 being highest) as follows: 1)
possessing predicted TM domain(s), signal peptide or GPI anchor and exhibiting spectral evi-
dence of incorporation of the biotin tag; 2) exhibiting spectral evidence of incorporation of the
biotin tag but lacking predicted TM domain(s), signal peptide or GPI anchor; 3) possessing
predicted TM domain(s), signal peptide or GPI anchor but lacking spectral evidence of incor-
poration of the biotin tag; 4) lacking predicted TM domain(s), signal peptide or GPI anchor as
well as lacking spectral evidence of incorporation of the biotin tag. Tiers one, two and three
were considered high-quality candidate surface proteins. Proteins identified from fewer than
two peptides and three PSMs in at least one sample were not assigned priority tiers.
Results
Proteomic analysis of P. vivax field isolate-derived salivary gland
sporozoites
MS-based proteomics was used to survey the proteins present in P. vivax salivary gland sporo-
zoites. Two independent sporozoite samples were obtained from mosquitoes fed on blood
obtained from volunteers who presented with clinical malaria at treatment centers in Thailand.
Peptide spectrum matches were analyzed using the Trans-Proteomic Pipeline [24]. Proteins
identified with scores corresponding to an FDR less than 1.0% were reported. A total of 1711
P. vivax proteins were identified from 3.5 × 106 sporozoites bearing the VK210 haplotype of
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circumsporozoite protein (CSP), of which 1492 (87.2%) were identified by at least two non-
degenerate peptides. A total of 1747 P. vivax proteins were identified from 4.5 × 106 sporozo-
ites bearing the VK247 CSP haplotype, of which 1572 (90.0%) were identified by at least two
non-degenerate peptides. A combined total of 1970 P. vivax proteins were identified from the
two samples, of which 1733 (88.0%) were identified from at least two non-degenerate peptides
in at least one of the samples. Of the combined 1970 P. vivax proteins identified, 1488 (75.5%)
were identified in both samples (S2 Table). Label-free protein quantification based on spectral
counts was used to compare protein abundance between the two samples. NSAF, a technique
that normalizes spectral counts for protein length and sample complexity, was used to com-
pare relative protein abundance within and between the two samples, while protein abundance
ratios between the two samples were tested for significance using the G-test as well as informa-
tion extracted from the normal distribution of protein ratios. Comparing the protein abun-
dances showed largely similar protein composition and protein abundance (Fig 1). The
proteins identified in both samples included all of the proteins in the top quartile of abundance
in each sample and 968 of 983 proteins (98.5%) in the upper half of abundance in each sample.
Furthermore, 218 of 223 (97.8%) of the proteins unique to the VK210 sample were in the
lower half of abundance, with 155 (69.5%) in the bottom quartile. Likewise, of the proteins
unique to the VK247 sample, 249 of 259 (96.1%) were in the lower half of abundance, with 192
(74.1%) in the bottom quartile. These results suggest that differences in proteins detected
between the two samples arose primarily from technical issues affecting limit-of-detection
rather than unique protein expression in one sample or the other. Likewise, observed differ-
ences in relative protein abundance observed between the two samples were likely predomi-
nantly technical in origin rather than biological. The populations of ln(NSAF) values from the
two field isolate samples could be fitted with Gaussian curves with similar means and variance,
and the population of log-transformed abundance ratios for proteins detected in both samples
assumed a normal distribution with a mean near zero, i.e., a protein ratio of essentially 1:1 (S1
Fig). Fitting the population of ratios to a Gaussian allowed measurement of the deviation from
the mean of 1:1, which was low (less than one standard deviation) for high-abundance proteins
and generally increased at lower protein abundances (Fig 1A), a known phenomenon of spec-
tral counting [39, 44]. To identify proteins with significantly different abundances between the
two samples, a likelihood ratio test (G-test) was applied to the protein ratios obtained from
comparing spectral counts of each protein as observed in the two samples [40]. All spectral
counts were increased by 1 in order to obtain ratios for proteins observed in only one sample
[40]. Additionally, a Gaussian curve was fit to the distribution of log-transformed abundance
ratios for proteins observed in both samples (Fig 1B) and the complementary error function
was used to obtain a p-value indicating the probability that the normal distribution was more
extreme than any give protein ratio. Combining these two tests identified protein ratios that
deviated significantly from the mean while accounting for the increased quantification error at
low spectral counts (Fig 1C). After correcting for multiple hypothesis testing by the Benja-
mini-Hochberg procedure, 119 proteins were identified with p-values corresponding to an
FDR less than 5.0% by both methods. Of these, 35 were identified in both samples (2.4% of all
proteins identified in both samples) and 84 were identified only in one sample or the other
(17% of all proteins identified in only one of the two samples; S2 Table).
In order to compare salivary gland sporozoite proteomes of P. vivax and P. falciparum, a
previously published proteomic analysis of P. falciparum salivary gland sporozoites [19] was
re-analyzed with the same informatics pipeline used here, identifying 2010 proteins, of which
1798 (89.5%) were identified by at least two peptides (S3 Table). The same quantitative
approach described above was used to compare the relative abundance of protein orthologs
between the two species. The spectral counting methods were expected to be less accurate
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Fig 1. Quantitative comparison of protein expression between two P. vivax salivary gland sporozoite field isolates. (A) Protein
abundances based on spectral counts were estimated using the normalized spectral abundance factor (NSAF). Each point represents the
natural log-transformed NSAF value of a protein, comparing its ln(NSAF) value in either sample. Deciles of relative abundance within each
sample are shown (dashed gray lines). For each protein observed in both of the two P. vivax salivary gland sporozoite samples, the natural
log of the protein ratio of the NSAF values observed in the VK210 sample and the VK247 sample was calculated as ln(NASF)VK210-ln
(NSAF)VK247. The population of these values produced a normal distribution centered near zero, corresponding to a mean ratio of 1:1 (S1
Fig). Proteins identified in both samples are color-coded to indicate the deviation of their log-transformed protein ratio R from the population
mean as determined from the fit curve. Deviation from the mean was low at high abundances and increased with decreasing spectral counts.
The cyan and orange points represent proteins identified in only one isolate or the other. (B) Protein ratios were calculated based on the
adjusted and normalized spectral counts used to calculate the G statistic. The population of log-transformed protein ratios of proteins
detected in both samples assumed a Gaussian distribution with a mean near zero. The mean and standard deviation from this distribution
were used to calculate p-values using the complementary error function (ERFC). (C) The protein ratios of all proteins detected in either
sample are plotted with respect to the sum of the adjusted and normalized PSM from both samples used to calculate the ratio for each
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when comparing orthologs between species than when comparing the same proteins detected
in different samples of the same species because, all else being equal, two protein orthologs
with sufficiently different sequences could produce different numbers of PSMs due to differ-
ences in the number of tryptic peptides produced and the detectability of these peptides by
LC-MS determined by sequence-specific chemical properties. Nonetheless, there was a large
overlap in both protein detection and relative protein abundance between protein orthologs
detected in the P. vivax and P. falciparum samples (Fig 2). Of the all the proteins detected in
either of the P. vivax samples or the P. falciparum sample, 2314 had annotated orthologs in
both P. falciparum and P. vivax, and 1609 of these (69.5%) were detected in the sporozoite
samples of both species analyzed here. As with the comparison between the two P. vivax sam-
ples, the population of log-transformed ratios of proteins identified in both P. vivax and P. fal-
ciparum had a mean near 1:1 with little deviation from the mean among the high-abundance
proteins and increasing deviation at low spectral counts. Most of the protein orthologs identi-
fied in one species and not the other were low-abundance proteins. Of the 332 orthologs not
detected in the P. falciparum sample, 300 (90.4%) were in the lower half of abundance and 189
(56.9%) were in the bottom quartile of abundance. Of the 373 orthologs not detected in the P.
vivax samples, 325 (87.1%) were in the lower half of abundance and 224 (60.1%) were in the
bottom quartile of abundance (S3 Table, Fig 2A). The most highly abundant proteins
detected in the P. vivax sporozoites were also highly abundant in P. falciparum sporozoites,
including several with critical roles in invasion, e.g., CSP, thrombospondin-related anonymous
protein (TRAP; PVP01_1218700, PF3D7_1335900), gamete egress and sporozoite traversal
protein (GEST; PVP01_1258000, PF3D7_1449000), cell traversal protein for ookinetes and
sporozoites (CelTOS; PVP01_1435400, PF3D7_1216600), apical membrane antigen 1 (AMA1;
PVP01_0934200, PF3D7_1133400), sporozoite invasion-associated protein 1 (SIAP1;
PVP01_0307900, PF3D7_0408600), and sporozoite protein essential for cell traversal (SPECT1
PVP01_1212300, PF3D7_1342500) (Table 1). Even so, a number of high-abundance proteins
were identified that were of significantly higher abundance in one species than the other (S3
Table). For example, PVP01_0314600 (conserved Plasmodium protein, unknown function)
was in the top decile of abundance in both P. vivax sporozoite samples, while its syntenic
ortholog PF3D7_0718900 (conserved Plasmodium protein, unknown function) was not
detected in the P. falciparum sporozoite sample, or for that matter, in any of the P. falciparum
proteomics datasets on PlasmoDB spanning the entire P. falciparum lifecycle. In the P.
falciparum sporozoite sample, two conserved Plasmodium proteins of unknown function,
PF3D7_0215200 and PF3D7_0410500, were in the top decile of protein abundance but not
detected at all in either P. vivax sample. Both proteins are up-regulated in P. falciparum salivary
gland sporozoites based on transcriptomic and proteomic data compiled at PlasmoDB.org. In
addition to differentially expressed orthologs, a number of identified proteins had no orthologs
in the other species compared. Of the combined 1970 P. vivax proteins identified, 29 (1.47%)
had no P. falciparum ortholog. These included three proteins annotated as PIR proteins (Plas-
modium interspersed repeats, species-specific immunovariant proteins [34, 45]) and 17 unan-
notated proteins (i.e., “conserved Plasmodium protein, unknown function”). The most
abundant P. vivax protein with no P. falciparum ortholog identified in the samples was a puta-
tive 6-Cys domain protein (PVP01_0303900). This protein was in the top decile of abundance
protein. Points in red are proteins with that were not significant at a 5.0% false discovery rate (FDR) according to the G-test. Points in green
are proteins with ratios that were not significant at a 5.0% FDR according to the ERFC. Points in blue are proteins ratios that were significant
by both cut-offs. Points inside of dashed boxes represent proteins detected in only one sample or the other. Protein ratios were estimated for
these proteins by increasing all spectral counts by one in order to give all proteins non-zero values.
https://doi.org/10.1371/journal.pntd.0005791.g001
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Fig 2. Quantitative comparison of protein expression between P. vivax and P. falciparum salivary gland sporozoites. (A) Protein
abundances based on spectral counts were estimated using the normalized spectral abundance factor (NSAF). Each point represents the
natural log-transformed NSAF value of a protein, comparing its ln(NSAF) value in either sample. P. vivax ln(NSAF) values are the average of
the values observed in the two field isolate samples. Deciles of relative abundance within each sample are shown (dashed gray lines). For
each protein with orthologs detected in both P. falciparum and P. vivax salivary gland sporozoites, the natural log of the protein ratio of the
NSAF values observed in the P. falciparum sample and the P. vivax sample was calculated as ln(NASF)P.falciparum-ln(NSAF)P.vivax. The
population of these values produced a normal distribution centered near zero, corresponding to a mean ratio of 1:1 (S2 Fig). Protein
orthologs detected in both species are color-coded to indicate the deviation of their log-transformed protein ratio R from the population mean
as determined from the fit curve. Deviation from the mean was low at high abundances and increased with decreasing spectral counts. The
cyan and orange points represent protein orthologs identified in only one species or the other. Diamond points represent proteins with no
ortholog in the other species. (B) Protein ratios were calculated based on the adjusted and normalized spectral counts used to calculate the
G statistic. The population of log-transformed protein ratios of proteins detected in both samples assumed a Gaussian distribution with a
mean near zero. The mean and standard deviation from this distribution were used to calculate p-values using the complementary error
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in both P. vivax samples, and is putatively surface-exposed on salivary gland sporozoites (dis-
cussed below).
Mass spectra were searched against the P. vivax P01 reference proteome [34] (PlasmoDB
v.31[29]). Current high-throughput MS approaches require a precise knowledge of the
genome of the organism under study; a protein can only be identified if its exact sequence is
contained in the database against which the mass spectra are searched. Because the samples
were obtained from field isolates and not laboratory strains, they were expected to contain pro-
tein sequence polymorphisms that would not be represented in the reference proteome. In
order to increase the likelihood of identifying isolate-specific polymorphisms, the P. vivax pro-
tein database against which the mass spectra were searched was augmented with potential
polymorphisms obtained from genomic and transcriptomic analyses of Thai P. vivax field iso-
lates. A total of 13 RNA-seq and 19 DNA-seq data sets were aligned against the P. vivax Sal1
reference genome and a reference proteome was generated containing any protein with an
amino acid sequence differing from the reference. Only 22% of the proteins in the reference
proteome had completely conserved sequences across all 33 datasets (the 32 field isolates plus
the reference genome). Over 50% of the proteins had four or more unique amino acid
sequences arising from various combinations of sequence polymorphisms, and 10% had 15 or
more unique sequences. One protein, RNA pseudouridylate synthase (PVX_080660) had a
unique sequence in all 33 genomes aligned (S4 Table). These P. vivax Sal-1 variants and the P.
vivax Sal-1 reference proteome were appended to the P. vivax P01 reference proteome and
used to identify polymorphisms in the analyzed samples. A total of 301 identified P. vivax
proteins contained polymorphisms that were not present in the P. vivax P01 reference
proteome (S5 Table). The four identified P. vivax salivary gland sporozoite proteins exhibiting
the most polymorphisms not present in the P. vivax P01 reference proteome were surface
proteins: AMA1 (PVP01_0934200), TRAP-like protein (TLP; PVP01_1132600), TRAP
(PVP01_1218700) and GPI-anchored micronemal protein (GAMA; PVP01_0505600). Each of
these proteins also exhibited a high degree of polymorphism in the compared field isolate
genomes (95th, 89th, 98th, and 97th percentiles, respectively, of the number of unique protein
sequences arising from polymorphisms among the compared genomes). Except for seven pro-
teins identified from a single peptide, all of these polymorphism-bearing proteins could be
detected without the additional knowledge of polymorphisms obtained from the field isolates.
However, failing to detect peptides would have led to increased errors in protein quantification
by spectral counts. Furthermore, knowledge of non-synonymous substitutions in the P. vivax
genome was critical to accurately characterizing proteins detected in the samples. For example,
the P. vivax haplotype designations VK210 and VK247 are based on differences in the
sequence of the repeat region of CSP. The VK210 haplotype bears tandem repeats of the
sequence GDRA(D/A)GQPA, while the VK247 haplotype bears tandem repeats of the
sequence ANGA(G/D)(N/D)QPG. In the VK247 whole proteome analyzed here, the repeat
region of CSP was poorly detected due to a lack of Lys or Arg residues that would result in
tryptic peptides. However, hundreds of PSMs identified a tryptic peptide at the C-terminal end
of the tandem repeat region which is distinct in VK247 [35], and no independent evidence was
observed for VK210-specific peptides (S3 Fig, S5 Table). Conversely, in the VK210 sample,
function (ERFC). (C) The protein ratios of all protein orthologs detected in either species are plotted with respect to the sum of the adjusted
and normalized PSM from both samples used to calculate the ratio for each protein. Points in red are proteins with that were not significant at
a 5.0% false discovery rate (FDR) according to the G-test. Points in green are proteins with ratios that were not significant at a 5.0% FDR
according to the ERFC. Points in blue are proteins ratios that were significant by both cut-offs. Points inside of dashed boxes represent
protein orthologs detected in only one species or the other. Protein ratios were estimated for these proteins by increasing all spectral counts
by one in order to give all proteins non-zero values.
https://doi.org/10.1371/journal.pntd.0005791.g002
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Table 1. Highly abundant proteins identified in P. vivax salivary gland sporozoites.
Abundance rank
(of 1970)a
Gene ID Protein Description P. falciparum orthologb P. falciparum
abundance rank (of
2010)c
1 PVP01_0905800 H4 histone H4, putative PF3D7_1105000 1
2 PVP01_1218700 TRAP thrombospondin-related anonymous
protein, putative
PF3D7_1335900 4
3 PVP01_0518800 HSP20 small heat shock protein HSP20,
putative
PF3D7_0816500 8
4 PVP01_0808400 null tubulin beta chain, putative PF3D7_1008700 2
5 PVP01_1244000 GAPDH glyceraldehyde-3-phosphate
dehydrogenase, putative
PF3D7_1462800 11
6 PVP01_0835600 CSP circumsporozoite (CS) protein PF3D7_0304600 6
7 PVP01_1463200 ACT1 actin PF3D7_1246200 9
8 PVP01_0905900 H2B histone 2B, putative PF3D7_1105100 5
9 PVP01_0717700 TrxL1 thioredoxin-like protein 1, putative PF3D7_0919300 17
10 PVP01_1114800,
PVP01_1114900
null elongation factor 1-alpha, putative PF3D7_1357000,
PF3D7_1357100
7
11 PVP01_1258000 GEST gamete egress and sporozoite traversal
protein, putative
PF3D7_1449000 12
12 PVP01_0517100 14-3-3I 14-3-3 protein, putative PF3D7_0818200 14
13 PVP01_1311000 PfpUB polyubiquitin 5, putative PF3D7_1211800 N/Ad
14 PVP01_1030500 ADF1 actin-depolymerizing factor 1, putative PF3D7_0503400 3
15 PVP01_0934200 AMA1 apical membrane antigen 1 PF3D7_1133400 20
16 PVP01_1020600 PNP purine nucleoside phosphorylase,
putative
PF3D7_0513300 29
17 PVP01_1435400 CelTOS cell traversal protein for ookinetes and
sporozoites
PF3D7_1216600 91
18 PVP01_0307900 SIAP1 sporozoite invasion-associated protein
1, putative
PF3D7_0408600 23
19 PVP01_1262200 FBPA fructose 1,6-bisphosphate aldolase,
putative
PF3D7_1444800 25
20 PVP01_0702100 null alpha tubulin 1, putative PF3D7_0903700 15
21 PVP01_1008000 IMC1g inner membrane complex protein 1g,
putative
PF3D7_0525800 60
22 PVP01_1212300 SPECT1 sporozoite protein essential for cell
traversal, putative
PF3D7_1342500 68
23 PVP01_1425700 null conserved Plasmodium protein,
unknown function
PF3D7_0814600 24
24 PVP01_1444500 HAD2 haloacid dehalogenase-like hydrolase,
putative
PF3D7_1226300 97
25 PVP01_0920700 PGM1 phosphoglycerate mutase, putative PF3D7_1120100 26
26 PVP01_0938800 SPELD sporozoite surface protein essential for
liver stage development, putative
PF3D7_1137800 10
27 PVP01_0918300 RAN GTP-binding nuclear protein RAN/TC4,
putative
PF3D7_1117700 61
28 PVP01_0505600 GAMA GPI-anchored micronemal antigen PF3D7_0828800 79
29 PVP01_1229700 LDH L-lactate dehydrogenase PF3D7_1324900 21
30 PVP01_0728100 null G2 protein, putative PF3D7_0929600 30
31 PVP01_1306500 null conserved Plasmodium protein,
unknown function
PF3D7_1207400 37
32 PVP01_0819300 H2A.Z histone H2A.Z, putative PF3D7_0320900 39
33 PVP01_1454700 null p25-alpha family protein, putative PF3D7_1236600 56
34 PVP01_1212200 MyoA myosin A, putative PF3D7_1342600 18
(Continued )
Proteogenomic analysis of Plasmodium vivax salivary gland sporozoites
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005791 July 31, 2017 15 / 36
peptides covering the entire CSP tandem repeat region were identified from hundreds of
PSMs, owing to the presence of regularly interspersed Arg tryptic cleavage sites. Interestingly,
the VK210 sample appeared to contain a mixed infection of at least two distinct field isolates.
The same discriminating peptide at the C-terminal end of the tandem repeat region was
identified by hundreds of PSMs for semi-tryptic fragments of various lengths containing the
VK210-specific sequence found in the P. vivax P01 reference proteome. However, a semi-tryp-
tic variant of the peptide found in the P. vivax Sal-1 version of CSP was also identified, as were
semi-tryptic peptides matching portions of the VK247 version of the peptide. There was not
enough independent evidence to determine if the VK247 haplotype was present in the sample
(S3 Fig, S5 Table). Evidence for a mixed infection was also found in TRAP. Seven sequence
polymorphisms not present in the P. vivax P01 reference proteome were identified in TRAP in
the samples analyzed, four of which were present in the P. vivax Sal-1 reference proteome and
three of which were only found in field isolates. As was observed for CSP, the VK247 sample
appeared to contain a single haplotype of TRAP, while there were at least two haplotypes of
TRAP in the VK210 sample (S4 Fig, S5 Table). In addition to accurate quantification and cor-
rect characterization of proteins, knowledge of sample-specific polymorphisms was critical to
identifying post-translational modifications (discussed below).
Post-translational modifications
It was recently shown that CSP and TRAP are glycosylated in P. falciparum salivary gland sporo-
zoites [20]. Here we report that these proteins are similarly modified in P. vivax sporozoites. The
motif CX2-3(S/T)CXXG in thrombospondin repeat (TSR) domains can be modified with an O-
linked fucose at the Ser/Thr [46], and this fucose can be further modified with glucose to pro-
duce a β1,3-linked disaccharide [47, 48]. Additionally, the WXXW and WXXC motifs of TSR
domains can be modified with a C-linked mannose at Trp [49, 50]. These potential glycosylation
motifs are present in the TSR domains of both CSP and TRAP in all Plasmodium species. The
TSR domain of P. vivaxCSP contains the tryptic peptide ATVGTEWTPCSVTCGVGVR with
potential O-fucosylation and C-mannosylation sites. Modification of the peptide with O-linked
glycans could not be directly detected by the spectral search engines due to the fact that O-linked
glycans are highly labile in the gas phase [51, 52] and are lost during collision-induced dissocia-
tion (CID) used to generate the identifying fragment spectra. However, as was previously dem-
onstrated with P. falciparum salivary gland sporozoites [20], it was possible to infer the presence




Gene ID Protein Description P. falciparum orthologb P. falciparum
abundance rank (of
2010)c
35 PVP01_1411700 null RNA-binding protein, putative PF3D7_1310700 46
a) Proteins ranked in order of decreasing abundance using the normalized spectral abundance factor.
b) Syntenic orthologs in P. falciparum as annotated in PlasmoDB.
c) Protein abundance ranks from proteomic analysis of P. falciparum salivary gland sporozoites [19] re-analyzed with the same software and parameters
used here.
d) Polyubiquitin (PF3D7_1211800) has extensive regions of identical sequence with ubiquitin-60S ribosomal protein L40 (PF3D7_1365900). In the P.
falciparum sample, all peptides identifying polyubiquitin were shared with L40. Peptides specific to L40 but none specific to polyubiquitin were identified, so
by the parsimony rules of ProteinProphet, all identifying spectra were assigned to L40 (giving it an abundance rank of 19) and polyubiquitin was not
considered identified. Non-degenerate peptides unique to both orthologs were identified in the P. vivax samples (S2 and S3 Tables).
https://doi.org/10.1371/journal.pntd.0005791.t001
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analysis showed that this peptide was modified with a mass matching that of an O-linked deoxy-
hexose. No evidence for C-mannose was observed (Fig 3). While neither the identity of the
deoxyhexose nor its attachment site in the peptide could be determined from the data, we pre-
sume it to be a fucose attached to the C-terminal Thr based on knowledge of the sugars and
enzymes present in Plasmodium [53], TSR domains in other species, and the fact that this resi-
due has been shown to be O-fucosylated in crystal structures of PfCSP expressed in mammalian
cells [54]. Evidence for O-fucosylation of CSP was observed in both samples. Based on the signal
intensity of the LC peaks, it appears that the majority of CSP (~90%) was glycosylated while a
portion was unmodified (S5 and S6 Figs). In P. falciparum sporozoites, the majority of CSP was
also observed to be modified with a single deoxyhexose while a small portion was unmodified,
though some CSP was also observed to be further modified with an additional hexose, consistent
with O-linked fucose-β1,3-glucose [20]. No evidence for modification of CSP with a disaccha-
ride was observed in these P. vivax sporozoite samples.
The TSR domain of P. vivax TRAP contains the tryptic peptide VANCGPWDPWTACSV
TCGR which includes potential O-fucosylation and C-mannosylation motifs. Critically, the
TRAP in the VK247 sample and some of the TRAP in the mixed-infection VK210 sample
exhibited an Arg!Lys substitution at this peptide. Knowledge of this polymorphism was only
obtained from the field isolate genomes, so lacking that data would have prevented detecting
glycosylation in the samples bearing the substitution. As with CSP, TRAP was observed to be
modified with a gas-phase labile modification (S7 and S8 Figs) which was presumed to be O-
fucose attached at the C-terminal Thr, again based on the TSR motif as well as crystal struc-
tures of PvTRAP and PfTRAP expressed in mammalian cells [55]. C-mannosylation of the
WDPWTAC sequence was not observed (Fig 1), even though in P. falciparum sporozoites the
C-terminal Trp of WDEWSPC was modified with a mass matching that of hexose, likely C-
mannose [20]. Based on chromatographic peak areas, virtually all TRAP in both samples was
completely glycosylated (S7 and S8 Figs).
Fig 3. Glycosylation of CSP and TRAP in P. vivax and P. falciparum salivary gland sporozoites. The
glycosylated portions of the conserved thrombospondin repeat (TSR) domains of P. falciparum and P. vivax
CSP and TRAP are aligned. The conserved glycosylation motif is highlighted. Residues that are putatively
glycosylated according to the MS evidence are colored as shown in the legend. Information on glycosylation
of P. falciparum is from [20]. Only TRAP in P. falciparum salivary gland sporozoites exhibited evidence for C-
mannosylation. Both CSP and TRAP exhibited evidence for O-fucosylation in both species. In P. falciparum, a
portion of CSP and TRAP also showed evidence for modification with a fucose-glucose disaccharide. No
evidence for the disaccharide was observed in the P. vivax samples.
https://doi.org/10.1371/journal.pntd.0005791.g003
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The MS data were further analyzed for evidence of protein phosphorylation, a reversible
PTM that is often involved in signaling and control of cellular function. Proteomic analysis of
phosphoproteins has been performed for asexual stages of P. falciparum [56–60] but not sporo-
zoites. Typical phosphoproteomic analyses employ affinity techniques to enrich for phosphor-
ylated peptides prior to LC-MS. While that approach was not feasible for this study due to the
limited sample material available, it was still possible to detect the presence of this modification
in proteins that were highly abundant and/or heavily modified in the samples. Evidence for
phosphorylation was found for a total of 139 proteins in either or both of the samples (S6 and
S7 Tables). Among the detected phosphoproteins with GO terms, the most prevalent func-
tional class was proteins with DNA or RNA-binding activity (21.6% of the phosphoproteins)
and the second most prevalent class was proteins with ATP activity, e.g., ATP binders, kinases
and phosphatase (20.9% of the phosphoproteins). Also well-represented were components
of the gliding machinery, including Myosin A (MyoA; PVP01_1212200), the glideosome-
associated proteins GAP40 (PVP01_1018200), GAP45 (PVP01_1440900) and GAPM2
(PVP01_0532000), several inner membrane complex (IMC) proteins, and the calcium-depen-
dent protein kinase CDPK1 (PVP01_0407500). The P. falciparum salivary gland sporozoite
data were searched in the same fashion, identifying 91 phosphorylated proteins (S6 and S8
Tables). All but four of these had syntenic orthologs in P. vivax, and 48 of these (55%) were
among the phosphoproteins identified from the P. vivax samples. The list of sporozoite phos-
phoproteins was compared against thirteen proteomic analyses of P. falciparum blood-stage
parasites [16, 56–66] (including five analyses of phosphopeptides enriched from blood-stage
parasites [56–60]) and three proteomic analyses of P. vivax blood-stage parasites [61, 67, 68]
available on PlasmoDB.org. The majority (74%) of phosphoproteins identified from either P.
vivax or P. falciparum sporozoites were also identified in phosphorylated form in P. falciparum
blood stages (S6 Table). Table 2 lists 16 P. vivax sporozoite phosphoproteins whose orthologs
were identified in P. falciparum blood stages but for which no evidence of phosphorylation
was observed, potentially representing sporozoite-specific phosphorylation. Table 3 lists 18 P.
vivax sporozoite phosphoproteins that were not detected at all (either phosphorylated or
unphosphorylated) in proteomic analyses of P. falciparum and P. vivax blood stages, represent-
ing known and potentially novel proteins specific to the sporozoite stage.
Identification of surface-exposed proteins
In order to identify surface-exposed proteins on P. vivax salivary gland sporozoites, a chemical
labeling approach was employed based on the recent analyses of the P. falciparum salivary
gland sporozoite surface proteome [19, 20]. Live sporozoites were labeled with a membrane-
impermeable, amine-reactive tag that covalently labeled solvent-exposed lysines with a biotin
tag. The parasites were then lysed and labeled proteins were recovered with streptavidin beads.
Two parasite samples were analyzed, one containing 2 × 106 sporozoites bearing the VK210
CSP haplotype and one containing 1.8 × 107 sporozoites bearing the VK247 CSP haplotype.
The VK247 sample was split in two and half was left unlabeled in order to assess non-specific
binding. A total of 90 Plasmodium proteins were identified from the VK210 sample, of which
61 (68%) were identified from two or more peptides, and 221 Plasmodium proteins were iden-
tified from the labeled VK247 sample, of which 147 (67%) were identified from two or more
peptides. The combined samples identified 239 Plasmodium proteins, of which 72 (30%) were
identified in both samples. The 129 proteins identified from two or more peptides and three or
more PSM in at least one sample were taken for further analysis. Some proteins could be seen
to exhibit direct evidence for incorporation of the biotin label in the identifying mass spectra.
Absence of spectral evidence for labeling does not mean that the protein was not labeled [69],
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but observing labeling in highly abundant sporozoite surface proteins such as CSP and TRAP
provides evidence that the labeling and enrichment protocol successfully identified surface-
exposed proteins. The non-specific binding was very low—only eight Plasmodium proteins
were identified from the unlabeled sporozoites (five identified from two or more peptides)
Table 2. Proteins phosphorylated in sporozoites but not in blood stagesa.
Gene ID P. falciparum
ortholog






PVP01_1310200 PF3D7_1211000 - kinesin-7, putative YES YES ATP binding, ATPase activity,
microtubule motor activity
PVP01_0836200 PF3D7_0304000 IMC1a inner membrane complex
protein 1a, putative
YES - -
PVP01_1128100 PF3D7_0621400 ALV7 inner membrane complex
protein 1j, putative
YES - -
PVP01_1341000 PF3D7_1407700 - conserved Plasmodium
protein, unknown function
- YES -
PVP01_1225100 PF3D7_1329400 - AMP deaminase, putative - - AMP deaminase activity
PVP01_0211800 PF3D7_0102900 - aspartate—tRNA ligase,
putative
- - ATP binding, aspartate-tRNA ligase
activity, nucleic acid binding
PVP01_0215600 PF3D7_0729900 - dynein heavy chain,
putative
- - ATP binding, ATPase activity,
microtubule motor activity
PVP01_0702400 PF3D7_0904000 - GTPase-activating
protein, putative
- - Rab GTPase activator activity
PVP01_0420400 PF3D7_0204700 HT hexose transporter - - substrate-specific transmembrane
transporter activity
PVP01_1212000 PF3D7_1342800 PEPCK phosphoenolpyruvate
carboxykinase, putative
- - ATP binding, phosphoenolpyruvate
carboxykinase (ATP) activity
PVP01_0505000 PF3D7_0829400 - prolyl 4-hydroxylase
subunit alpha, putative
- - L-ascorbic acid binding, iron ion
binding, oxidoreductase activity,
acting on paired donors, with
incorporation or reduction of
molecular oxygen
PVP01_1102300 PF3D7_1369700 - U2 small nuclear
ribonucleoprotein A’,
putative
- - protein binding
PVP01_1249600 PF3D7_1457300 - conserved Plasmodium
protein, unknown function
- - binding
PVP01_0811600 PF3D7_1011500 - conserved Plasmodium
protein, unknown function
- - -
PVP01_1454300 PF3D7_1236200 - conserved Plasmodium
protein, unknown function
- - protein binding
PVP01_1411500 PF3D7_1310500 - conserved protein,
unknown function
- - carbohydrate binding
a) A combined total of 139 P. vivax proteins were identified with evidence for phosphorylation from proteomic analyses of two different salivary gland
sporozoite samples. Presented in this table are the 16 proteins whose orthologs were not detected in phosphorylated form in any of six published
phosphoproteomic analyses of P. falciparum blood stages [56–60] available from PlasmoDB and yet were still detectable in P. falciparum blood stages in
any of the 13 proteomic analyses [16, 56–66] available from PlasmoDB. The complete list of detected phosphoproteins is provided in S6 Table, and the
complete list of detected phosphopeptides is provided in S7 and S8 Tables.
b) “YES” indicates that the protein was also detected with phosphorylation in the re-analysis of the previously published P. falciparum salivary gland
sporozoite proteome presented here.
c) “YES” indicates that the protein is annotated as up-regulated in salivary gland sporozoites in PlasmoDB, either identified as up-regulated in the Winzeler
OPI gene expression data or identified as a Sporozoite Conserved Orthologous Transcript (SCOT).
d) Protein functions are annotated and/or predicted GO terms obtained from PlasmoDB v.32.
https://doi.org/10.1371/journal.pntd.0005791.t002
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Table 3. Phosphorylated sporozoite-specific proteinsa.
Gene ID P. falciparum
ortholog






PVP01_1015000 PF3D7_0518900 - conserved Plasmodium
protein, unknown function
YES YES -
PVP01_1439700 PF3D7_1221400 IMC1h inner membrane complex
protein 1h, putative
YES - -
PVP01_0518800 PF3D7_0816500 HSP20 small heat shock protein
HSP20, putative
YES - -
PVP01_1427900 PF3D7_0812300 SSP3 sporozoite surface protein
3, putative
YES - -
PVP01_0938800 PF3D7_1137800 SPELD sporozoite surface protein
essential for liver stage
development, putative
YES - -
PVP01_0945700 PF3D7_1145000 - conserved Plasmodium
protein, unknown function
YES - ATP binding, actin binding,




PVP01_0415300 PF3D7_0209500 - conserved Plasmodium
protein, unknown function
YES - GTP binding, GTPase activity,
translation initiation factor activity
PVP01_1032700 PF3D7_0502300 - conserved Plasmodium
protein, unknown function
YES - -
PVP01_1259500 PF3D7_1447500 IMC20 conserved Plasmodium
protein, unknown function
YES - -
PVP01_1432200 PF3D7_1213400 - conserved Plasmodium
protein, unknown function
YES - -
PVP01_1218700 PF3D7_1335900 TRAP thrombospondin-related
anonymous protein,
putative
- YES host cell surface receptor binding
PVP01_1448500 PF3D7_1230300 SPM2 subpellicular microtubule
protein 2, putative
- - transferase activity
PVP01_1132600 PF3D7_0616500 TLP TRAP-like protein,
putative
- - -
PVP01_1124700 PF3D7_0624800 - conserved Plasmodium
protein, unknown function
- - ATP binding
PVP01_0813500 PF3D7_1013400 - conserved Plasmodium
protein, unknown function
- - ATP binding
PVP01_1425600 PF3D7_0814700 null conserved Plasmodium
protein, unknown function
- - -
PVP01_0947000 - - conserved Plasmodium
protein, unknown function
- - -
PVP01_0609000 - - conserved Plasmodium
protein, unknown function
- - -
a) A combined total of 139 P. vivax proteins were identified with evidence for phosphorylation from proteomic analyses of two different salivary gland
sporozoite samples. Presented in this table are the 18 proteins that were not detected in any of the of the 13 proteomic analyses of blood stage P.
falciparum [16, 56–66] available from PlasmoDB.org. The complete list of detected phosphoproteins is provided in S6 Table, and the complete list of
detected phosphopeptides is provided in S7 and S8 Tables.
b) “YES” indicates that the protein was also detected with phosphorylation in the re-analysis of the previously published P. falciparum salivary gland
sporozoite proteome presented here.
c) “YES” indicates that the protein is annotated as up-regulated in salivary gland sporozoites in PlasmoDB.org, either identified as up-regulated in the
Winzeler OPI gene expression data or identified as a Sporozoite Conserved Orthologous Transcript (SCOT).
d) Protein functions are annotated and/or predicted GO terms obtained from PlasmoDB v.32.
https://doi.org/10.1371/journal.pntd.0005791.t003
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compared to the 221 Plasmodium proteins identified from an equal number of labeled sporo-
zoites from the same sample. The eight Plasmodium proteins in the control were identified by
49 PSMs, more than 30-fold fewer than the 1604 PSMs obtained from the labeled sample (S9
Table). The labeled and unlabeled VK247 sporozoites were split from the same batch of puri-
fied sporozoites and, except for the labeling steps, were processed identically in parallel along
with the labeled VK210 sample, including lysis, capture on magnetic biotin beads, washes, elu-
tion, SDS-PAGE and in-gel digestion, and all three samples were analyzed by LC-MS one after
the other on the same column. As such, the raw number of spectral counts gives the best esti-
mate of relative abundance when comparing the relative abundance of a protein identified in
both the labeled and unlabeled VK247 samples. Seven of the eight proteins identified from the
unlabeled control were also identified in the labeled sample. Although there was insufficient
data to assess statistically significant enrichment of labeled versus unlabeled proteins, all seven
proteins were at least two-fold more abundant in the labeled sample based on the number of
PSM. Proteins identified in the unlabeled control included the known sporozoite surface pro-
teins TRAP and sporozoite surface protein essential for liver stage development (SPELD;
PVP01_0938800) [70], as well as actin (PVP01_1463200), which has been detected on the sur-
face of ookinetes [71]. These proteins exhibited direct evidence from the identifying mass spec-
tra that they had been labeled with the biotin tag the labeled samples. They were also among
the most abundant proteins in the sporozoite proteome (top 2%), so their presence among
non-specifically binding proteins is not surprising. Given the above, the contribution of non-
specific binding to the proteins identified in both samples was assumed to be minimal. In
order to rule out low-confidence identifications, only proteins identified from two or more
peptides and three or more PSM were taken for further analysis.
Although the biotin tag for surface labeling is putatively membrane-impermeable [72],
based on previous work, some portion of sporozoites were assumed to have compromised
plasma membranes, resulting in labeling of intracellular proteins [20, 73]. Therefore, com-
bined theoretical and experimental evidence were used to identify the strongest candidates for
surface-exposed proteins from among all those identified by the surface protein enrichment
strategy. Proteins that were identified with high confidence as described above were assigned a
priority tier (1 being highest) as follows: Tier 1) possessing predicted transmembrane (TM)
domain(s), signal peptide or glycophosphatidylinositol (GPI) anchor and exhibiting spectral
evidence of incorporation of the biotin tag; 2) exhibiting spectral evidence of incorporation of
the biotin tag but lacking predicted TM domain(s), signal peptide or GPI anchor; 3) possessing
predicted TM domain(s), signal peptide or GPI anchor but lacking spectral evidence of incor-
poration of the biotin tag; 4) lacking predicted TM domain(s), signal peptide or GPI anchor as
well as lacking spectral evidence of incorporation of the biotin tag. These criteria produced a
list of 36 high-quality candidate surface proteins (Table 4). Of these, 31 orthologs were also
detected by similar analyses of putatively surface-exposed proteins on P. falciparum [20] or P.
yoelii [74] salivary gland sporozoites. Several of these are known to be secreted and/or surface-
exposed on sporozoites, including CSP, TRAP, SPELD [70], GEST, sporozoite surface protein
3 (SSP3; PVP01_1427900), hexose transporter (HT; PVP01_0420400) and CelTOS.
Discussion
The sole function of a Plasmodium sporozoite injected into the skin of the host during a mos-
quito bite is to find its way to the liver and initiate liver stage development. To achieve this
aim, the parasite must be mobile, traverse various tissue barriers, and finally recognize and
infect a hepatocyte in the liver. These complex processes rely on interaction of various parasite
proteins with the host tissues and represent a bottleneck of Plasmodium infection, as only
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Table 4. Putatively surface-exposed proteins on P. vivax salivary gland sporozoites.








1 PVP01_0835600 CSP circumsporozoite (CS) protein 2 Labeled,
Signal, GPI
Enriched, Labeled Detected
1 PVP01_0938800 SPELD sporozoite surface protein essential for liver
stage development, putative
2 Labeled, TM Enriched, Labeled Detected





1 PVP01_1258000 GEST gamete egress and sporozoite traversal
protein, putative
1 Labeled, Signal Detected Detected
2 PVP01_1463200 actin 2 Labeled Enriched, Labeled Detected
2 PVP01_1227100 conserved Plasmodium protein, unknown
function
2 Labeled Detected -
2 PVP01_0602700 conserved Plasmodium protein, unknown
function
2 Labeled Enriched -
2 PVP01_1212200 myosin A, putative 2 Labeled Enriched, Labeled Detected
2 PVP01_1311000 polyubiquitin 5, putative 2 Labeled Enriched Detected
2 PVP01_0518800 HSP20 small heat shock protein HSP20, putative 2 Labeled Enriched -
2 PVP01_1268100 TPx1 thioredoxin peroxidase 1, putative 2 Labeled Enriched Detected
3 PVP01_0303900 6-cysteine protein, putative, pseudogene 2 Signal, GPI NO ORTHOLOG NO
ORTHOLOG
3 PVP01_0621700 ADT ADP/ATP transporter on adenylate
translocase, putative
2 3 TMs Enriched -
3 PVP01_0934200 AMA1 apical membrane antigen 1 2 TM Enriched -
3 PVP01_1435400 CelTOS cell traversal protein for ookinetes and
sporozoites
2 TM - -
3 PVP01_0532000 GAPM2 glideosome associated protein with multiple
membrane spans 2, putative
2 5 TMs Enriched Detected
3 PVP01_1341900 GAPM3 glideosome associated protein with multiple
membrane spans 3, putative
2 6 TMs Enriched Detected
3 PVP01_1018200 GAP40 glideosome-associated protein 40, putative 2 9 TMs Enriched -
3 PVP01_0716400 GAP50 glideosome-associated protein 50, putative 2 TM, Signal Enriched -
3 PVP01_0505600 GAMA GPI-anchored micronemal antigen 2 Signal, GPI Enriched Detected
3 PVP01_0716300 HSP70-
2
heat shock protein 70, putative 2 Signal Enriched -
3 PVP01_0420400 HT hexose transporter 2 12 TMs Enriched Detected
3 PVP01_1229700 LDH L-lactate dehydrogenase 2 TM Enriched Detected
3 PVP01_0308000 PLP1 perforin-like protein 1 2 TM Enriched Detected
3 PVP01_1255000 RON2 rhoptry neck protein 2 2 TM, Signal Detected -
3 PVP01_0307900 SIAP1 sporozoite invasion-associated protein 1,
putative
2 Signal Enriched Detected
3 PVP01_1427900 SSP3 sporozoite surface protein 3, putative 2 TM, Signal Enriched Detected
3 PVP01_0714500 TRX3 thioredoxin 3, putative 2 TM - -
3 PVP01_1132600 TLP TRAP-like protein, putative 2 TM, Signal - -
3 PVP01_1339600 conserved Plasmodium protein, unknown
function
1 4 TMs Enriched -
3 PVP01_1455800 conserved protein, unknown function 1 5 TMs, GPI Enriched -
3 PVP01_0710400 ICP inhibitor of cysteine proteases, putative 1 Signal Detected -
3 PVP01_1025800 longevity-assurance (LAG1) protein, putative 1 6 TMs Enriched -
3 PVP01_0948400 MAEBL membrane associated erythrocyte binding-
like protein, putative
1 TM, Signal - Detected
(Continued )
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small fraction of sporozoites produced in a mosquito makes it to the host liver. Impediment of
the parasite-host interaction presents an opportunity to interfere with the parasite life cycle.
Presented here is an effort to identify and characterize the proteins in P. vivax salivary
gland sporozoites. While the total number of proteins identified with high confidence is com-
parable to the most comprehensive analyses of its kind performed on P. falciparum and P. yoe-
lii sporozoites [19], the list of identified proteins presented here is not assumed to be complete.
The shotgun proteomics methods for high-throughput proteomic profiling employed here are
inherently biased toward highly abundant proteins and are affected by sample complexity and
the dynamic range of protein concentrations. These limitations are especially pronounced
when analyzing mosquito-stage Plasmodium parasites. Obtaining sufficient sample material
for analysis is difficult, as it requires dissecting hundreds of mosquitoes and extracting the spo-
rozoites from the salivary glands. There is unavoidable loss of sporozoites during the purifica-
tion process, but this step is absolutely critical, otherwise the signal from contaminating
mosquito proteins masks parasite peptides in the mass spectrometer. Assuming that there are
more proteins present in sporozoites than detected here, the identification of these proteins
will likely require further improvements in techniques for purifying large numbers of sporozo-
ites along with continued improvements in mass spectrometer detection limit and duty cycle.
Previous efforts to catalogue the protein complement of Plasmodium sporozoites have used
laboratory strains, whereas the sporozoites analyzed in this work were obtained from clinical
samples isolated from natural infections. Because of the scarcity of the samples, each of the
four samples analyzed here (two whole-proteome and two surface-enriched) were different
field isolates of P. vivax. To account for expected polymorphism among field isolates, the mass
spectra were searched against a reference proteome supplemented with protein sequences
bearing polymorphisms observed in 32 different Thai field isolates. This analysis showed that
301 proteins in the samples exhibited sequence polymorphisms not found in the P. vivax P01
reference proteome. While nearly all of these of proteins could have been identified from con-
served peptides present in the reference proteome, knowledge of polymorphisms gained from
genomic and transcriptomic analyses of field isolates was critical for accurate analysis of the
samples. At a qualitative level, the VK210 and VK247 haplotypes of CSP could be confirmed,
and the VK210 whole proteome sample appeared to have contained a mixed infection of at
Table 4. (Continued)








3 PVP01_0317900 RALP1 rhoptry-associated leucine zipper-like protein
1
1 Signal - -
3 PVP01_0929700 SpdSyn spermidine synthase, putative 1 TM Enriched -
(a) Proteins were assigned priority tiers (1 is highest) based on experimental and theoretical evidence. Tier 1 = protein had predicted characteristics of a
surface protein (transmembrane domain (TM), signal peptide, or glycophosphatidylinositol (GPI) anchor) and evidence for incorporation of the biotin label
was observed in the identifying mass spectra. Tier 2 = spectral evidence for label only. Tier 3 = TM, signal peptide, or GPI anchor only.
(b) Indicates if protein was identified in one or both of the surface labeled replicate samples.
(c) Evidence used to assign tiers in (a). “Labeled” indicates evidence for incorporation of the biotin label was observed in the identifying mass spectra.
Predicted characteristics of surface proteins are listed: transmembrane domain (TM), signal peptide, or glycophosphatidylinositol anchor (GPI).
(d) Evidence for the protein being surface-exposed in P. falciparum salivary gland sporozoites [20]. “Enriched” indicates the protein was significantly more
abundant in labeled samples versus unlabeled controls based on statistical analysis from multiple biological replicates. “Detected” indicates that the protein
was detected but was not significantly enriched. “-” indicates there is an annotated P. vivax ortholog that was not detected.
(e) Evidence for the protein being surface exposed in P. yoelii salivary gland sporozoites [74]. “Detected” indicates the protein was detected in either of two
biological replicates. Evidence for labeling was not assessed in that experiment. “-” indicates there is an annotated P. vivax ortholog that was not detected.
https://doi.org/10.1371/journal.pntd.0005791.t004
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least two different VK210 field isolates. Additionally, it was not possible to detect O-fucosyla-
tion of TRAP in some of the samples without the knowledge that the TRAP peptide containing
the O-fucosylated Thr can contain an Arg!Lys substitution, a polymorphism that was present
in a third of the analyzed field isolate genomes but in neither the P. vivax Sal-1 nor the P. vivax
P01 reference proteomes. Protein quantification by spectral counting revealed important
information about the relative abundance of proteins within and between salivary gland sporo-
zoite samples of the same species and across species. The high-throughput proteomics meth-
ods employed here require exact knowledge of the protein sequence in order to detect
component peptides, thus accurate quantification of proteins bearing amino acid substitutions
required knowledge of protein sequence polymorphisms that were not reflected in the refer-
ence proteome.
Label-free protein quantification based on spectral counting was used to compare relative
protein abundance within and among samples. In addition to comparing the two P. vivax sali-
vary gland sporozoite proteomes to each other, a union list of identified P. vivax proteins was
compared with a P. falciparum salivary gland sporozoite dataset obtained from re-analysis of
published proteomic data [19]. The quantitative data was useful for identifying general trends,
e.g., highly abundant proteins that were identified in all datasets or proteins that were abun-
dant in one species but whose orthologs were conspicuously absent in another. Identifying a
protein in one sample and not the other when comparing two similar samples is common in
MS-based proteomics; a protein may not be detected because it is truly absent in the sample,
because it is below the detection limit of the instrument, or due to some technical issue such as
interference from some other species in the sample or the stochastic sampling of the ion stream
by the mass analyzer [75]. In the comparison of the two P. vivax salivary gland sporozoite sam-
ples, the proteins identified in one sample but not the other were primarily low-abundance,
suggesting that detection limit was the primary source of differences in proteome coverage
between the two samples. Likewise, when the relative abundance of any given protein was
compared between the two samples, high-abundance samples showed little deviation from the
population mean of a 1:1 ratio, while the deviation tended to increase at lower concentrations.
This increasing deviation with decreasing spectral counts is a known phenomenon in spectral
counting methods [39, 44]. Statistical tests based on independent assessment of protein ratios
as well as the population of protein abundances in the samples were used to identify proteins
with significantly different protein abundance between samples. When biological replicates
are feasible, it is common to employ a paired t-test of protein abundance ratios obtained from
spectral counts [38]. When biological replicates are not available, a conservative likelihood
ratio test, the G-test, can be applied to the pooled spectral counts from LC-MS technical repli-
cates [40, 44]. The advantage of this test for spectral counting is that at low spectral counts
where quantification error is high, only the largest protein ratios achieve significance. How-
ever, at high spectral counts, even protein ratios near 1:1 can be assigned significance. Based
on the observation that the population of log-transformed abundance ratios of proteins
detected in both samples was Gaussian, it could be assumed that only proteins at the extreme
ends of the distribution were truly significant, and the complementary error function provided
a p-value as a metric for this deviation. In conjunction with the G-test to eliminate spuriously
large protein ratios obtained from low spectral counts, it was possible to identify a small num-
ber of proteins that may have had truly different protein expression between the two P. vivax
samples (though technical sources of variance cannot be ruled out). Conversely, the analysis
showed that the majority of identified proteins exhibited similar protein expression levels in
the field isolates examined. Such observations are of value when considering targets for novel
vaccines or therapeutics. The same quantitative approach used to compare the two P. vivax
samples also enabled comparison of the P. vivax and P. falciparum samples and demonstrated
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that for most proteins identified in one species, the ortholog was identified at a similar relative
abundance in the other species, especially among high-abundance proteins. In addition to pro-
teins identified in each species for which there is no annotated ortholog in the other species,
the significance thresholds provided by the statistical tests identified a number of proteins with
putatively different expression in the two species that warrant further exploration, including
proteins identified in one species whose ortholog was not detected at all in the other. Further
investigation will be required to determine if these sorts of proteins are truly expressed at
greater levels in P. vivax compared to P. falciparum and whether they may play a specialized
role in P. vivax biology.
Examining the curated functional annotation of the Plasmodium proteome revealed that
many of the proteins that are known or predicted to be involved in invasion in blood stages or
in sporozoites of different Plasmodium species are also expressed in P. vivax sporozoites. Multi-
ple annotation sources were combined in order to compile a list of dense granule, microneme,
rhoptry, rhoptry neck, and glideosome proteins, and protein detection was compared between
P. vivax and P. falciparum salivary gland sporozoites (Fig 4, S10 Table). There was a very high
Fig 4. Comparison Invasion-related proteins identified in P. vivax and P. falciparum salivary gland
sporozoites. Proteins identified from proteomic analyses of P. vivax and P. falciparum salivary gland sporozoites
were compared against a compendium of known and putative invasion-related Plasmodium proteins (S10 Table).
Proportional Venn diagrams show the number of proteins in each category identified only in P. vivax (cyan), only in
P. falciparum (orange), in both species (green) and neither species (gray). The total number of proteins identified in
each species and the total number of proteins in the category are listed below each diagram.
https://doi.org/10.1371/journal.pntd.0005791.g004
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overlap in the invasion-related proteins detected in the two species, and the handful of proteins
detected in only one species or the other were detected only at low abundance. For example,
the most abundant of these invasion-related proteins identified in P. vivax but not P. falcipa-
rum was the micronemal protein merozoite TRAP-like protein (MTRAP; PVP01_0613800).
This protein was confidently identified in both of the P. vivax samples analyzed here, though
only in the second quartile of relative abundance. Its syntenic ortholog (PF3D7_1028700) was
not among the 2010 proteins identified from P. falciparum sporozoites, but the transcript of
MTRAP has previously been detected in P. falciparum salivary gland sporozoites [76], suggest-
ing that the failure to detect this protein by proteomics may reflect limit of detection rather
than true biological difference between the two Plasmodium species.
In addition to detecting the proteins present in P. vivax salivary gland sporozoites, the data
were analyzed for evidence of post-translational modifications, specifically phosphorylation
and glycosylation. Protein phosphorylation is of interest for development of antimalarial drugs
[77, 78] because the reversible modification is involved in regulation of essentially every aspect
of the complex Plasmodium life cycle, yet the parasite and the mammalian host are sufficiently
phylogenetically divergent that many Plasmodium protein kinases can, in theory, be selectively
inhibited [78, 79]. Although the limited amount of starting material available for this work pre-
cluded phosphopeptide enrichment, 139 proteins were identified with evidence of phosphory-
lation, and the orthologs of 48 of these were also phosphorylated in P. falciparum salivary
gland sporozoites. The most prevalent functional class of proteins exhibiting phosphorylation
was proteins involved in transcriptional and translational regulation, including DNA- and
RNA-binding proteins and transcription and translation factors, suggesting active phosphory-
lation-mediated regulation of gene expression in this stage. Many of these proteins were also
among the other prevalent class of proteins, those with ATP binding activity. Components of
the gliding motility machinery were also well-represented among the observed phosphopro-
teins, including MyoA, the glideosome-associated proteins GAP40 and GAP45, several inner
membrane complex (IMC) proteins, and the calcium-dependent protein kinase CDPK1. A
phosphoproteomic analysis of P. falciparum schizonts [58] found evidence that phosphoryla-
tion helps to regulate the glideosome machinery, and in vitro work confirmed that GAP45,
MyoA, and CDPK1, which are proteins important for motility of the merozoites that emerge
from blood-stage schizonts, are substrates of protein kinase A. That these proteins are also
phosphorylated in sporozoites suggests that phosphorylation also plays a role in regulating
gliding motility in sporozoites. Recently, a glideosome-associated connector (GAC) protein
has been identified which links the adhesin MIC2 (the Toxoplasma gondii ortholog of
Plasmodium TRAP) to F-actin and is essential for motility and invasion [80]. P. vivaxGAC
(PVP01_1110200) was in the top decile of protein abundance in the samples analyzed here.
Over half of the GAC in P. vivax sporozoites was phosphorylated at Ser10 or Ser15 on the pro-
tein N-terminus, and approximately 30% of the protein was phosphorylated at Ser1495 or
Ser1496 on a section bearing homology to a protein-binding armadillo-type fold (ARM).
Ser1496 on the same peptide in P. falciparum was approximately 38% phosphorylated in the
salivary gland sporozoite data analyzed here. Previous phosphoproteomic analyses identified
eight different phosphosites on GAC in P. falciparum blood stages [56–60], several of them on
regions of conserved sequence between P. falciparum and P. vivax. The ARM phosphosite seen
in P. vivax and P. falciparum sporozoites was also observed in P. falciparum blood stages, but
the N-terminal phosphosites were not. AMA1 plays a role in adhesion of merozoites to eryth-
rocytes, though its role is dispensable for rodent Plasmodium sporozoite invasion of hepato-
cytes [81]. The role of AMA1 in human-infecting Plasmodium sporozoites is currently
undetermined. The protein has a single transmembrane domain near its C-terminus that
serves as an anchor to the parasite plasma membrane. Previous proteomic analyses have
Proteogenomic analysis of Plasmodium vivax salivary gland sporozoites
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005791 July 31, 2017 26 / 36
shown that several residues on the cytoplasmic tail of AMA1 are phosphorylated in blood
stage parasites [56–60], and mutating these residues to prevent phosphorylation resulted in a
defect in invasion of erythrocytes [82]. AMA1 in P. falciparum shares an identical sequence
with P. vivax at the C-terminus. In the P. vivax sporozoite samples analyzed here, the cyto-
plasmic tail of AMA1 was observed with a single phosphorylation at Ser551, Thr553 or Thr554
(corresponding to Ser610, Thr612 and Thr613 in P. falciparum). In the P. falciparum salivary
gland sporozoite data re-analyzed here, nearby Ser588 on the cytoplasmic tail was phosphory-
lated. In the P. falciparum and both P. vivax sporozoite samples, the peptides containing the
respective phosphosites were never observed in unmodified form, suggesting AMA1 is consti-
tutively phosphorylated in salivary gland sporozoites. These conserved residues have been
observed to be variably phosphorylated in AMA1 in P. falciparum blood stages [56, 59, 60].
These results suggest that phosphorylation of AMA1 plays a role in regulating the protein’s
function in sporozoites, perhaps by mediating attachment to the glideosome.
Importantly, many of the phosphoproteins identified in the sporozoite samples have not
been observed to be phosphorylated in the handful of blood-stage phosphoproteomes pub-
lished to-date, including several proteins known to be specific to the sporozoite stage. Among
these stage-specific phosphoproteins are proteins known to be located on the sporozoite sur-
face. For example, it has been previously determined that sporozoite surface protein 3 (SSP3;
PVP01_1427900, PF3D7_0812300) is found on the surface of P. yoelii and P. falciparum sali-
vary gland sporozoites [19, 20, 83], and here we show that it is likely surface-exposed in P.
vivax sporozoites as well. The role of SSP3 is not fully understood, but initial work suggests
that it plays a role in gliding motility [83]. Approximately 30% of SSP3 in P. vivax sporozoites
was phosphorylated at Ser440 near the C-terminus of the protein. A single predicted trans-
membrane domain at residues 402–424 is likely the point where the protein is anchored to the
membrane, placing the phosphosite on the cytosolic portion of the protein. Approximately
40% of SSP3 in P. falciparum sporozoites was similarly phosphorylated at the C-terminal cyto-
plasmic tail at either or both of two Ser residues, Ser456 (the P. falciparum counterpart of the
P. vivax S440 phosphosite) or nearby Ser459. Further experimentation will be required to elu-
cidate any role phosphorylation might play in the function of this and other phosphorylated
sporozoite surface proteins, as well any effect on their antigenicity.
It has been recently shown that the major sporozoite surface proteins CSP and TRAP are
glycosylated at their TSR domains in P. falciparum salivary gland sporozoites [20] and the data
presented here now show that these proteins are also glycosylated in P. vivax sporozoites. Strik-
ingly, both CSP and TRAP in P. vivaxwere modified only with a single deoxyhexose (presum-
ably O-fucose), whereas in P. falciparum, CSP was observed with either a deoxyhexose or a
deoxyhexose-hexose disaccharide (likely O-fucose-β-1,3-glucose), and TRAP was observed
with the O-linked mono- or disaccharide as well as with a C-linked hexose (likely C-mannose).
The reason for this difference is not immediately clear. The monosaccharide-modified ver-
sions of TRAP and CSP were the dominant forms in both P. falciparum and P. vivax sporozo-
ites, and a putative O-fucosyltransferase POFUT2 (PF3D7_0909200, PVP01_0707700), which
could hypothetically add O-fucose to TSR domains, was observed to be expressed in sporozo-
ites of both species. In P. falciparum sporozoites, the dissacharide-modified versions of CSP
and TRAP were present at lower abundance than the monosaccharide-modified versions, so it
is conceivable that in the P. vivax samples the disaccharide-modified versions were present but
at concentrations below the detection limit. It is also possible that the necessary glycosyltrans-
ferase was not expressed. While no putative β-1,3-glucosyltransferase for adding glucose to O-
fucose has been identified in Plasmodium, PfPIESP1 (PF3D7_0310400) has been identified as
having sequence homology with human β-1,3-glucosyltransferase and possesses putative
glycosyltransferase domains [20]. PIESP1 was expressed in P. falciparum salivary gland
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sporozoites [19], but its P. vivax homolog (PVP01_0829800) was barely detected in the P.
vivax sporozoites analyzed here (identified by a only two PSMs in one sample and not at all in
the other). The absence of C-linked hexose on TRAP in the P. vivax sporozoites analyzed here
was unequivocal. Unlike O-linked glycans, C-mannose is not gas-phase labile and withstands
collision-induced dissociation, giving rise to peptide fragment ions that precisely identify the
residue to which the modification is attached. Furthermore, some portion of the C-mannose
undergoes cross-ring fragmentation that gives rise to neutral loss species that further corrobo-
rate the identity of the C-mannose [20]. The glycosylated TRAP peptide was identified by doz-
ens of spectra in the P. vivax samples, none of which contained evidence for modified Trp. A
putative C-mannosyltransferase (PF3D7_0806200, PVP01_0114300) that could hypothetically
add C-mannose to TSR domains was expressed in both P. falciparum [19] and P. vivax sporo-
zoites, though this function has yet to be verified experimentally. Interestingly, this disparity in
glycosylation was also observed in TRAP expressed in mammalian cells: PfTRAP was C-man-
nosylated but PvTRAP was not [55]. It is notable that in PvTRAP, the sequence where it would
be expected to find C-mannosylation contains prolines that could affect the secondary struc-
ture of the motif and disrupt recognition by the glycosyltransferase. Further studies will be
required to determine whether the observed differences in CSP and TRAP glycosylation
between P. falciparum and P. vivax are due to differences in enzyme function or some other
technical or biological reason. Importantly for design of vaccine antigens, O-fucosylation of
CSP and TRAP almost certainly affect antigenicity of the proteins. Structural studies of these
proteins have shown that the glycans project above the protein surface and yet have structur-
ally constrained orientations [54, 55, 84], and studies of the conserved TSR domain in other
species have shown that fucosylated amino acids may be viewed as surrogate amino acids [85],
so the protein and carbohydrate elements create unique combinatorial epitopes.
A chemical labeling approach was used to enrich proteins that are surface-exposed on sali-
vary gland sporozoites. As previously discussed [20, 73], this surface biotinylation approach is
known to produce spurious results due to labeling of cytosolic proteins presumably arising
from a portion of sporozoites that exhibit compromised plasma membranes, an inevitable
byproduct of the excessive sample handling involved in dissecting, purifying, and labeling the
parasites. The data presented here were curated with theoretical and experimental information
to select those identified proteins that are the most likely to be truly surface-exposed and pro-
teins were assigned priority tiers based on this evidence in order to identify high-quality candi-
dates for future efforts to validate and test these proteins as vaccine antigens. This approach is
supported by the fact that the list of high-quality candidates includes several known sporozoite
surface proteins, including CSP, TRAP, SSP3, and SPELD. Additionally, cross-referencing the
results with similar analyses of P. falciparum [20] and P. yoelii [74] salivary gland sporozoites
revealed a large overlap in the proteins that the technique identified across species. A notable
exception was a 6-Cys protein (PVP01_0303900) that has no ortholog in P. falciparum or P.
yoelii but does have syntenic orthologs in the more closely related malaria parasites P. knowlesi
and P. cynomolgi. In other Plasmodium species, other 6-cys proteins are known to be found on
the sporozoite surface and to play a role in liver invasion [20, 86]. Future studies will determine
what role this putative surface protein may have in sporozoites and if it will be useful as a
vivax-specific antigen.
The putatively surface-exposed proteins identified here as well as in P. falciparum and P.
yoelii sporozoites included known cytosolic proteins. While there remains the possibility
that these results represent experimental artifact as discussed, there is increasing evidence
that cytosolic proteins can have “moonlighting” roles and be found on the cell surface
of Plasmodium and other organisms. For example, the chaperone HSP70-2 (BiP) has
been shown to localize at the surface of certain cell types in other organisms [87], and
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HSP70-2/BiP (PVP01_0716300, PF3D7_0917900) was identified as putatively surface-
exposed in both P. vivax and P. falciparum salivary gland sporozoites. Another protein
classified as a heat shock protein, HSP20, has been identified by biotinylation of sporozoite
surface proteins in both P. falciparum and P. vivax sporozoites. This protein has been dem-
onstrated to be surface-exposed in P. berghei salivary gland sporozoites by immunoelectron
microscopy [88]. Other intracellular proteins repeatedly identified as surface-exposed by the
surface labeling technique include components of the gliding motility machinery, including
actin, MyoA, glideosome-associated proteins (GAP), and inner membrane complex (IMC)
proteins. Immunofluorescence assays of un-permeabilized P. falciparum salivary gland spo-
rozoites showed that the glideosome proteins GAP45 and MTIP were accessible to antibodies
during gliding [20], though whether this was due to relocation of the proteins to the sporozo-
ite surface or permeability of the plasma membrane in gliding sporozoites is not known.
Similarly, immunofluorescence identified actin, which is part of the gliding machinery, at
the ookinete surface [71]. Another glideosome-associated protein, GAP50, has been shown
to relocate to the surface of gametes where it binds complement regulator proteins and inac-
tivates human complement in the blood meal that would otherwise induce lysis of the para-
site [89]. Taken together, this information suggests that even “known” intracellular proteins
identified by this surface labeling method can reflect truly surface-exposed proteins and war-
rant further investigation.
In conclusion, the MS-based proteomics methods employed here enabled the most compre-
hensive identification to-date of proteins and their post-translational modifications present in
P. vivax sporozoites. Combined with the identification of putatively surface-exposed proteins
of P. vivax salivary gland sporozoites, these results suggest that the complement of surface-
exposed proteins on salivary gland sporozoites may contain many unexpected as well as post-
translationally modified proteins that warrant further experimentation to verify their localiza-
tion and assess their suitability as vaccine antigens.
Supporting information
S1 File. Extended methods.
(DOCX)
S2 File. P. vivax Sal-1 proteins with variant sequences. All P. vivax proteins identified from
DNA-seq and RNA-seq analyses of Thai field isolates whose protein sequences differ from the
P. vivax Sal-1 reference proteome. File is in protein fasta format.
(ZIP)
S1 Fig. Distributions of NSAF values of identified P. vivax proteins.
(PDF)
S2 Fig. Distributions of NSAF values of identified P. vivax and P. falciparum proteins.
(PDF)
S3 Fig. Mass spectral evidence for circumsporozoite protein (CSP) haplotype.
(PDF)
S4 Fig. Mass spectrometry reveals sequence polymorphisms in thrombospondin-related
anonymous protein (TRAP).
(PDF)
S5 Fig. Evidence for glycosylation of CSP in P. vivax VK210 salivary gland sporozoites.
(PDF)
Proteogenomic analysis of Plasmodium vivax salivary gland sporozoites
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005791 July 31, 2017 29 / 36
S6 Fig. Evidence for glycosylation of CSP in P. vivax VK247 salivary gland sporozoites.
(PDF)
S7 Fig. Evidence for glycosylation of TRAP in P. vivax VK210 salivary gland sporozoites.
(PDF)
S8 Fig. Evidence for glycosylation of TRAP in P. vivax VK247 salivary gland sporozoites.
(PDF)
S1 Table. Extended LC-MS methods parameters.
(XLSX)
S2 Table. Proteins identified from whole proteome analysis of P. vivax salivary gland spo-
rozoites.
(XLSX)
S3 Table. Comparison of proteins identified from whole proteome analysis of P. falcipa-
rum and P. vivax salivary gland sporozoites.
(XLSX)
S4 Table. Frequency of protein sequence polymorphisms in Thai P. vivax strains.
(XLSX)
S5 Table. Protein sequence variants detected in P. vivax salivary gland sporozoites.
(XLSX)
S6 Table. Phosphoproteins identified in P. vivax and P. falciparum salivary gland sporozoites.
(XLSX)
S7 Table. Phosphorylated peptides identified from mass spectrometric analysis of P. vivax
salivary gland sporozoites.
(XLSX)
S8 Table. Phosphorylated peptides identified from mass spectrometric analysis of P. falcip-
arum salivary gland sporozoites.
(XLSX)
S9 Table. All proteins identified from surface labeling of live P. vivax salivary gland sporo-
zoites with biotin.
(XLSX)
S10 Table. Identification of invasion proteins in salivary gland sporozoites.
(XLSX)
Acknowledgments
We would like to thank the dedicated field sample collection and insectary staff at Mahidol
Vivax Research Center for providing P. vivax sporozoites, and Matt Fishbaugher for assistance
with mosquito dissection and sporozoite purification.
Author Contributions
Conceptualization: Kristian E. Swearingen, Sebastian A. Mikolajczak.
Formal analysis: Kristian E. Swearingen, Erika L. Flannery, Robert D. Morrison, Cristian
Koepfli.
Proteogenomic analysis of Plasmodium vivax salivary gland sporozoites
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005791 July 31, 2017 30 / 36
Funding acquisition: Kristian E. Swearingen, Ivo Muller, Aaron Jex, Robert L. Moritz, Stefan
H. I. Kappe, Jetsumon Sattabongkot, Sebastian A. Mikolajczak.
Investigation: Kristian E. Swearingen, Scott E. Lindner, Erika L. Flannery, Ashley M.
Vaughan, Rapatbhorn Patrapuvich, Cristian Koepfli.
Methodology: Kristian E. Swearingen, Scott E. Lindner, Rapatbhorn Patrapuvich, Aaron Jex,
Jetsumon Sattabongkot, Sebastian A. Mikolajczak.
Project administration: Sebastian A. Mikolajczak.
Resources: Kristian E. Swearingen, Scott E. Lindner, Rapatbhorn Patrapuvich, Ivo Muller,
Aaron Jex, Robert L. Moritz, Stefan H. I. Kappe, Jetsumon Sattabongkot, Sebastian A.
Mikolajczak.
Supervision: Sebastian A. Mikolajczak.
Writing – original draft: Kristian E. Swearingen.
Writing – review & editing: Kristian E. Swearingen, Scott E. Lindner, Erika L. Flannery, Rob-
ert L. Moritz, Stefan H. I. Kappe, Sebastian A. Mikolajczak.
References
1. Adekunle AI, Pinkevych M, McGready R, Luxemburger C, White LJ, Nosten F, et al. Modeling the
dynamics of Plasmodium vivax infection and hypnozoite reactivation in vivo. PLoS Negl Trop Dis. 2015;
9(3):e0003595. https://doi.org/10.1371/journal.pntd.0003595 PMID: 25780913
2. White NJ. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J. 2011; 10:297.
Epub 2011/10/13. https://doi.org/10.1186/1475-2875-10-297 PMID: 21989376
3. Price RN, Douglas NM, Anstey NM. New developments in Plasmodium vivax malaria: severe disease
and the rise of chloroquine resistance. Curr Opin Infect Dis. 2009; 22(5):430–5. https://doi.org/10.1097/
QCO.0b013e32832f14c1 PMID: 19571748
4. White NJ, Imwong M. Relapse. Advances in parasitology. 2012; 80:113–50. Epub 2012/12/04. https://
doi.org/10.1016/B978-0-12-397900-1.00002-5 PMID: 23199487
5. Bousema T, Drakeley C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax
gametocytes in relation to malaria control and elimination. Clin Microbiol Rev. 2011; 24(2):377–410.
Epub 2011/04/13. https://doi.org/10.1128/CMR.00051-10 PMID: 21482730
6. Wells TN, Burrows JN, Baird JK. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden
obstacle to malaria elimination. Trends in parasitology. 2010; 26(3):145–51. Epub 2010/02/06. https://
doi.org/10.1016/j.pt.2009.12.005 PMID: 20133198
7. Baird JK. Eliminating malaria—all of them. Lancet. 2010; 376(9756):1883–5. Epub 2010/11/03. https://
doi.org/10.1016/S0140-6736(10)61494-8 PMID: 21035840
8. John GK, Douglas NM, von Seidlein L, Nosten F, Baird JK, White NJ, et al. Primaquine radical cure of
Plasmodium vivax: a critical review of the literature. Malar J. 2012; 11:280. https://doi.org/10.1186/
1475-2875-11-280 PMID: 22900786
9. Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, et al. Primaquine failure and cyto-
chrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med. 2013; 369(14):1381–2. https://doi.org/
10.1056/NEJMc1301936 PMID: 24088113
10. Doolan DL, Hoffman SL. Pre-erythrocytic-stage immune effector mechanisms in Plasmodium spp.
infections. Philosophical transactions of the Royal Society of London Series B, Biological sciences.
1997; 352(1359):1361–7. Epub 1997/11/14. https://doi.org/10.1098/rstb.1997.0121 PMID: 9355128
11. Arevalo-Herrera M, Vasquez-Jimenez JM, Lopez-Perez M, Vallejo AF, Amado-Garavito AB, Cespedes
N, et al. Protective Efficacy of Plasmodium vivax Radiation-Attenuated Sporozoites in Colombian Vol-
unteers: A Randomized Controlled Trial. PLoS neglected tropical diseases. 2016; 10(10):e0005070.
https://doi.org/10.1371/journal.pntd.0005070 PMID: 27760143
12. Regules JA, Cummings JF, Ockenhouse CF. The RTS,S vaccine candidate for malaria. Expert Rev
Vaccines. 2011; 10(5):589–99. https://doi.org/10.1586/erv.11.57 PMID: 21604980
13. Bennett JW, Yadava A, Tosh D, Sattabongkot J, Komisar J, Ware LA, et al. Phase 1/2a Trial of Plasmo-
dium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety,
Proteogenomic analysis of Plasmodium vivax salivary gland sporozoites
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005791 July 31, 2017 31 / 36
Immunogenicity, and Efficacy. PLoS neglected tropical diseases. 2016; 10(2):e0004423. https://doi.
org/10.1371/journal.pntd.0004423 PMID: 26919472
14. White M, Amino R, Mueller I. Theoretical Implications of a Pre-Erythrocytic Plasmodium vivax Vaccine
for Preventing Relapses. Trends Parasitol. 2017; 33(4):260–3. https://doi.org/10.1016/j.pt.2016.12.011
PMID: 28077251
15. Yadava A, Waters NC. Rationale for Further Development of a Vaccine Based on the Circumsporozoite
Protein of Plasmodium vivax. PLoS Negl Trop Dis. 2017; 11(1):e0005164. https://doi.org/10.1371/
journal.pntd.0005164 PMID: 28081149
16. Florens L, Washburn MP, Raine JD, Anthony RM, Grainger M, Haynes JD, et al. A proteomic view of
the Plasmodium falciparum life cycle. Nature. 2002; 419(6906):520–6. Epub 2002/10/09. https://doi.
org/10.1038/nature01107 PMID: 12368866
17. Lasonder E, Janse CJ, van Gemert GJ, Mair GR, Vermunt AM, Douradinha BG, et al. Proteomic profil-
ing of Plasmodium sporozoite maturation identifies new proteins essential for parasite development and
infectivity. PLoS Pathog. 2008; 4(10):e1000195. Epub 2008/11/01. https://doi.org/10.1371/journal.ppat.
1000195 PMID: 18974882
18. Hall N, Karras M, Raine JD, Carlton JM, Kooij TW, Berriman M, et al. A comprehensive survey of the
Plasmodium life cycle by genomic, transcriptomic, and proteomic analyses. Science. 2005; 307
(5706):82–6. Epub 2005/01/08. https://doi.org/10.1126/science.1103717 PMID: 15637271
19. Lindner SE, Swearingen KE, Harupa A, Vaughan AM, Sinnis P, Moritz RL, et al. Total and putative sur-
face proteomics of malaria parasite salivary gland sporozoites. Mol Cell Proteomics. 2013; 12(5):1127–
43. https://doi.org/10.1074/mcp.M112.024505 PMID: 23325771
20. Swearingen KE, Lindner SE, Shi L, Shears MJ, Harupa A, Hopp CS, et al. Interrogating the Plasmodium
Sporozoite Surface: Identification of Surface-Exposed Proteins and Demonstration of Glycosylation on
CSP and TRAP by Mass Spectrometry-Based Proteomics. PLoS Pathog. 2016; 12(4):e1005606.
https://doi.org/10.1371/journal.ppat.1005606 PMID: 27128092
21. Kennedy M, Fishbaugher ME, Vaughan AM, Patrapuvich R, Boonhok R, Yimamnuaychok N, et al. A
rapid and scalable density gradient purification method for Plasmodium sporozoites. Malar J. 2012;
11:421. Epub 2012/12/19. https://doi.org/10.1186/1475-2875-11-421 PMID: 23244590
22. Kessner D, Chambers M, Burke R, Agus D, Mallick P. ProteoWizard: open source software for rapid
proteomics tools development. Bioinformatics. 2008; 24(21):2534–6. https://doi.org/10.1093/
bioinformatics/btn323 PMID: 18606607
23. Eng JK, Jahan TA, Hoopmann MR. Comet: an open-source MS/MS sequence database search tool.
Proteomics. 2013; 13(1):22–4. Epub 2012/11/14. https://doi.org/10.1002/pmic.201200439 PMID:
23148064
24. Deutsch EW, Mendoza L, Shteynberg D, Slagel J, Sun Z, Moritz RL. Trans-Proteomic Pipeline, a stan-
dardized data processing pipeline for large-scale reproducible proteomics informatics. Proteomics Clin
Appl. 2015. Epub 2015/01/30. https://doi.org/10.1002/prca.201400164 PMID: 25631240
25. Keller A, Nesvizhskii AI, Kolker E, Aebersold R. Empirical statistical model to estimate the accuracy of
peptide identifications made by MS/MS and database search. Anal Chem. 2002; 74(20):5383–92. Epub
2002/10/31. PMID: 12403597
26. Shteynberg D, Nesvizhskii AI, Moritz RL, Deutsch EW. Combining results of multiple search engines in
proteomics. Mol Cell Proteomics. 2013; 12(9):2383–93. https://doi.org/10.1074/mcp.R113.027797
PMID: 23720762
27. Nesvizhskii AI, Keller A, Kolker E, Aebersold R. A statistical model for identifying proteins by tandem
mass spectrometry. Anal Chem. 2003; 75(17):4646–58. Epub 2003/11/25. PMID: 14632076
28. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, et al. Genome sequence of the human
malaria parasite Plasmodium falciparum. Nature. 2002; 419(6906):498–511. https://doi.org/10.1038/
nature01097 PMID: 12368864
29. Aurrecoechea C, Brestelli J, Brunk BP, Dommer J, Fischer S, Gajria B, et al. PlasmoDB: a functional
genomic database for malaria parasites. Nucleic Acids Res. 2009; 37(Database issue):D539–43. Epub
2008/10/30. https://doi.org/10.1093/nar/gkn814 PMID: 18957442
30. Jiang X, Peery A, Hall AB, Sharma A, Chen XG, Waterhouse RM, et al. Genome analysis of a major
urban malaria vector mosquito, Anopheles stephensi. Genome Biol. 2014; 15(9):459. https://doi.org/10.
1186/s13059-014-0459-2 PMID: 25244985
31. Giraldo-Calderon GI, Emrich SJ, MacCallum RM, Maslen G, Dialynas E, Topalis P, et al. VectorBase:
an updated bioinformatics resource for invertebrate vectors and other organisms related with human
diseases. Nucleic Acids Res. 2015; 43(Database issue):D707–13. https://doi.org/10.1093/nar/gku1117
PMID: 25510499
Proteogenomic analysis of Plasmodium vivax salivary gland sporozoites
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005791 July 31, 2017 32 / 36
32. Carlton JM, Adams JH, Silva JC, Bidwell SL, Lorenzi H, Caler E, et al. Comparative genomics of the
neglected human malaria parasite Plasmodium vivax. Nature. 2008; 455(7214):757–63. https://doi.org/
10.1038/nature07327 PMID: 18843361
33. Jex A, Mueller I, Kappe SHI, Mikolajczak SA, Sattabongkot J, Patrapuvich R, et al. Integrated transcrip-
tomic, proteomic and epigenomic analysis of Plasmodium vivax salivary-gland sporozoites. bioRxiv.
2017. https://doi.org/10.1101/145250
34. Auburn S, Bohme U, Steinbiss S, Trimarsanto H, Hostetler J, Sanders M, et al. A new Plasmodium
vivax reference sequence with improved assembly of the subtelomeres reveals an abundance of pir
genes. Wellcome Open Res. 2016; 1:4. https://doi.org/10.12688/wellcomeopenres.9876.1 PMID:
28008421
35. Kim TS, Kim HH, Lee SS, Oh CM, Choi KM, Lin K, et al. Molecular cloning and expression of the VK247
circumsporozoite protein for serodiagnosis of variant form Plasmodium vivax. Parasitol Res. 2011; 108
(5):1275–82. https://doi.org/10.1007/s00436-010-2177-3 PMID: 21318386
36. Fermin D, Basrur V, Yocum AK, Nesvizhskii AI. Abacus: a computational tool for extracting and pre-pro-
cessing spectral count data for label-free quantitative proteomic analysis. Proteomics. 2011; 11
(7):1340–5. https://doi.org/10.1002/pmic.201000650 PMID: 21360675
37. Zhang Y, Wen Z, Washburn MP, Florens L. Refinements to label free proteome quantitation: how to
deal with peptides shared by multiple proteins. Anal Chem. 2010; 82(6):2272–81. https://doi.org/10.
1021/ac9023999 PMID: 20166708
38. Zybailov B, Mosley AL, Sardiu ME, Coleman MK, Florens L, Washburn MP. Statistical analysis of mem-
brane proteome expression changes in Saccharomyces cerevisiae. J Proteome Res. 2006; 5(9):2339–
47. Epub 2006/09/02. https://doi.org/10.1021/pr060161n PMID: 16944946
39. Gokce E, Shuford CM, Franck WL, Dean RA, Muddiman DC. Evaluation of normalization methods on
GeLC-MS/MS label-free spectral counting data to correct for variation during proteomic workflows. J
Am Soc Mass Spectrom. 2011; 22(12):2199–208. Epub 2011/09/29. https://doi.org/10.1007/s13361-
011-0237-2 PMID: 21952779
40. Hendrickson EL, Xia Q, Wang T, Leigh JA, Hackett M. Comparison of spectral counting and metabolic
stable isotope labeling for use with quantitative microbial proteomics. Analyst. 2006; 131(12):1335–41.
Epub 2006/11/25. https://doi.org/10.1039/b610957h PMID: 17124542
41. Krogh A, Larsson B, von Heijne G, Sonnhammer EL. Predicting transmembrane protein topology with a
hidden Markov model: application to complete genomes. J Mol Biol. 2001; 305(3):567–80. https://doi.
org/10.1006/jmbi.2000.4315 PMID: 11152613
42. Petersen TN, Brunak S, von Heijne G, Nielsen H. SignalP 4.0: discriminating signal peptides from trans-
membrane regions. Nat Methods. 2011; 8(10):785–6. https://doi.org/10.1038/nmeth.1701 PMID:
21959131
43. Pierleoni A, Martelli PL, Casadio R. PredGPI: a GPI-anchor predictor. BMC Bioinformatics. 2008;
9:392. https://doi.org/10.1186/1471-2105-9-392 PMID: 18811934
44. Old WM, Meyer-Arendt K, Aveline-Wolf L, Pierce KG, Mendoza A, Sevinsky JR, et al. Comparison of
label-free methods for quantifying human proteins by shotgun proteomics. Mol Cell Proteomics. 2005; 4
(10):1487–502. https://doi.org/10.1074/mcp.M500084-MCP200 PMID: 15979981
45. del Portillo HA, Fernandez-Becerra C, Bowman S, Oliver K, Preuss M, Sanchez CP, et al. A superfamily
of variant genes encoded in the subtelomeric region of Plasmodium vivax. Nature. 2001; 410
(6830):839–42. https://doi.org/10.1038/35071118 PMID: 11298455
46. Hofsteenge J, Huwiler KG, Macek B, Hess D, Lawler J, Mosher DF, et al. C-mannosylation and O-fuco-
sylation of the thrombospondin type 1 module. J Biol Chem. 2001; 276(9):6485–98. Epub 2000/11/09.
https://doi.org/10.1074/jbc.M008073200 PMID: 11067851
47. Sato T, Sato M, Kiyohara K, Sogabe M, Shikanai T, Kikuchi N, et al. Molecular cloning and characteriza-
tion of a novel human beta1,3-glucosyltransferase, which is localized at the endoplasmic reticulum and
glucosylates O-linked fucosylglycan on thrombospondin type 1 repeat domain. Glycobiology. 2006; 16
(12):1194–206. Epub 2006/08/11. https://doi.org/10.1093/glycob/cwl035 PMID: 16899492
48. Kozma K, Keusch JJ, Hegemann B, Luther KB, Klein D, Hess D, et al. Identification and characteriza-
tion of abeta1,3-glucosyltransferase that synthesizes the Glc-beta1,3-Fuc disaccharide on thrombos-
pondin type 1 repeats. J Biol Chem. 2006; 281(48):36742–51. Epub 2006/10/13. https://doi.org/10.
1074/jbc.M605912200 PMID: 17032646
49. Hofsteenge J, Muller DR, de Beer T, Loffler A, Richter WJ, Vliegenthart JF. New type of linkage
between a carbohydrate and a protein: C-glycosylation of a specific tryptophan residue in human
RNase Us. Biochemistry. 1994; 33(46):13524–30. Epub 1994/11/22. PMID: 7947762
50. Julenius K. NetCGlyc 1.0: prediction of mammalian C-mannosylation sites. Glycobiology. 2007; 17
(8):868–76. Epub 2007/05/12. https://doi.org/10.1093/glycob/cwm050 PMID: 17494086
Proteogenomic analysis of Plasmodium vivax salivary gland sporozoites
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005791 July 31, 2017 33 / 36
51. Macek B, Hofsteenge J, Peter-Katalinic J. Direct determination of glycosylation sites in O-fucosylated
glycopeptides using nano-electrospray quadrupole time-of-flight mass spectrometry. Rapid Commun
Mass Spectrom. 2001; 15(10):771–7. Epub 2001/05/10. https://doi.org/10.1002/rcm.298 PMID:
11344537
52. Wang LW, Leonhard-Melief C, Haltiwanger RS, Apte SS. Post-translational modification of thrombos-
pondin type-1 repeats in ADAMTS-like 1/punctin-1 by C-mannosylation of tryptophan. J Biol Chem.
2009; 284(44):30004–15. Epub 2009/08/13. https://doi.org/10.1074/jbc.M109.038059 PMID: 19671700
53. Cova M, Rodrigues JA, Smith TK, Izquierdo L. Sugar activation and glycosylation in Plasmodium. Malar
J. 2015; 14:427. https://doi.org/10.1186/s12936-015-0949-z PMID: 26520586
54. Doud MB, Koksal AC, Mi LZ, Song G, Lu C, Springer TA. Unexpected fold in the circumsporozoite pro-
tein target of malaria vaccines. Proc Natl Acad Sci U S A. 2012; 109(20):7817–22. Epub 2012/05/02.
https://doi.org/10.1073/pnas.1205737109 PMID: 22547819
55. Song G, Koksal AC, Lu C, Springer TA. Shape change in the receptor for gliding motility in Plasmodium
sporozoites. Proc Natl Acad Sci U S A. 2012; 109(52):21420–5. Epub 2012/12/14. https://doi.org/10.
1073/pnas.1218581109 PMID: 23236185
56. Treeck M, Sanders JL, Elias JE, Boothroyd JC. The phosphoproteomes of Plasmodium falciparum and
Toxoplasma gondii reveal unusual adaptations within and beyond the parasites’ boundaries. Cell Host
Microbe. 2011; 10(4):410–9. Epub 2011/10/25. https://doi.org/10.1016/j.chom.2011.09.004 PMID:
22018241
57. Solyakov L, Halbert J, Alam MM, Semblat JP, Dorin-Semblat D, Reininger L, et al. Global kinomic and
phospho-proteomic analyses of the human malaria parasite Plasmodium falciparum. Nat Commun.
2011; 2:565. Epub 2011/12/01. https://doi.org/10.1038/ncomms1558 PMID: 22127061
58. Lasonder E, Green JL, Camarda G, Talabani H, Holder AA, Langsley G, et al. The Plasmodium falcipa-
rum schizont phosphoproteome reveals extensive phosphatidylinositol and cAMP-protein kinase A sig-
naling. J Proteome Res. 2012; 11(11):5323–37. https://doi.org/10.1021/pr300557m PMID: 23025827
59. Pease BN, Huttlin EL, Jedrychowski MP, Talevich E, Harmon J, Dillman T, et al. Global analysis of pro-
tein expression and phosphorylation of three stages of Plasmodium falciparum intraerythrocytic devel-
opment. J Proteome Res. 2013; 12(9):4028–45. Epub 2013/08/07. https://doi.org/10.1021/pr400394g
PMID: 23914800
60. Lasonder E, Green JL, Grainger M, Langsley G, Holder AA. Extensive differential protein phosphoryla-
tion as intraerythrocytic Plasmodium falciparum schizonts develop into extracellular invasive merozo-
ites. Proteomics. 2015; 15(15):2716–29. https://doi.org/10.1002/pmic.201400508 PMID: 25886026
61. Acharya P, Pallavi R, Chandran S, Chakravarti H, Middha S, Acharya J, et al. A glimpse into the clinical
proteome of human malaria parasites Plasmodium falciparum and Plasmodium vivax. Proteomics Clin
Appl. 2009; 3(11):1314–25. Epub 2010/12/08. https://doi.org/10.1002/prca.200900090 PMID:
21136953
62. Oehring SC, Woodcroft BJ, Moes S, Wetzel J, Dietz O, Pulfer A, et al. Organellar proteomics reveals
hundreds of novel nuclear proteins in the malaria parasite Plasmodium falciparum. Genome Biol. 2012;
13(11):R108. https://doi.org/10.1186/gb-2012-13-11-r108 PMID: 23181666
63. Lasonder E, Rijpma SR, van Schaijk BC, Hoeijmakers WA, Kensche PR, Gresnigt MS, et al. Integrated
transcriptomic and proteomic analyses of P. falciparum gametocytes: molecular insight into sex-specific
processes and translational repression. Nucleic Acids Res. 2016; 44(13):6087–101. https://doi.org/10.
1093/nar/gkw536 PMID: 27298255
64. Silvestrini F, Lasonder E, Olivieri A, Camarda G, van Schaijk B, Sanchez M, et al. Protein export marks
the early phase of gametocytogenesis of the human malaria parasite Plasmodium falciparum. Mol Cell
Proteomics. 2010; 9(7):1437–48. Epub 2010/03/25. https://doi.org/10.1074/mcp.M900479-MCP200
PMID: 20332084
65. Florens L, Liu X, Wang Y, Yang S, Schwartz O, Peglar M, et al. Proteomics approach reveals novel pro-
teins on the surface of malaria-infected erythrocytes. Mol Biochem Parasitol. 2004; 135(1):1–11. Epub
2004/08/04. PMID: 15287581
66. Bowyer PW, Simon GM, Cravatt BF, Bogyo M. Global profiling of proteolysis during rupture of Plasmo-
dium falciparum from the host erythrocyte. Mol Cell Proteomics. 2011; 10(5):M110 001636. https://doi.
org/10.1074/mcp.M110.001636 PMID: 20943600
67. Moreno-Perez DA, Degano R, Ibarrola N, Muro A, Patarroyo MA. Determining the Plasmodium vivax
VCG-1 strain blood stage proteome. J Proteomics. 2014; 113C:268–80. https://doi.org/10.1016/j.jprot.
2014.10.003 PMID: 25316051
68. Roobsoong W, Roytrakul S, Sattabongkot J, Li J, Udomsangpetch R, Cui L. Determination of the Plas-
modium vivax schizont stage proteome. J Proteomics. 2011; 74(9):1701–10. https://doi.org/10.1016/j.
jprot.2011.03.035 PMID: 21515433
Proteogenomic analysis of Plasmodium vivax salivary gland sporozoites
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005791 July 31, 2017 34 / 36
69. Schiapparelli LM, McClatchy DB, Liu HH, Sharma P, Yates JR 3rd, Cline HT. Direct detection of biotiny-
lated proteins by mass spectrometry. J Proteome Res. 2014; 13(9):3966–78. Epub 2014/08/15. https://
doi.org/10.1021/pr5002862 PMID: 25117199
70. Al-Nihmi FM, Kolli SK, Reddy SR, Mastan BS, Togiri J, Maruthi M, et al. A Novel and Conserved Plas-
modium Sporozoite Membrane Protein SPELD is Required for Maturation of Exo-erythrocytic Forms.
Sci Rep. 2017; 7:40407. https://doi.org/10.1038/srep40407 PMID: 28067322
71. Hernandez-Romano J, Rodriguez MH, Pando V, Torres-Monzon JA, Alvarado-Delgado A, Lecona
Valera AN, et al. Conserved peptide sequences bind to actin and enolase on the surface of Plasmodium
berghei ookinetes. Parasitology. 2011; 138(11):1341–53. Epub 2011/08/06. https://doi.org/10.1017/
S0031182011001296 PMID: 21816124
72. Staros JV. N-hydroxysulfosuccinimide active esters: bis(N-hydroxysulfosuccinimide) esters of two
dicarboxylic acids are hydrophilic, membrane-impermeant, protein cross-linkers. Biochemistry. 1982;
21(17):3950–5. Epub 1982/08/17. PMID: 7126526
73. Wass MN, Stanway R, Blagborough AM, Lal K, Prieto JH, Raine D, et al. Proteomic analysis of Plasmo-
dium in the mosquito: progress and pitfalls. Parasitology. 2012; 139(9):1131–45. Epub 2012/02/18.
https://doi.org/10.1017/S0031182012000133 PMID: 22336136
74. El-Manzalawy Y, Munoz EE, Lindner SE, Honavar V. PlasmoSEP: Predicting surface-exposed proteins
on the malaria parasite using semisupervised self-training and expert-annotated data. Proteomics.
2016; 16(23):2967–76. https://doi.org/10.1002/pmic.201600249 PMID: 27714937
75. Karpievitch YV, Dabney AR, Smith RD. Normalization and missing value imputation for label-free LC-
MS analysis. BMC Bioinformatics. 2012; 13 Suppl 16:S5. Epub 2012/11/28. https://doi.org/10.1186/
1471-2105-13-S16-S5 PMID: 23176322
76. Le Roch KG, Zhou Y, Blair PL, Grainger M, Moch JK, Haynes JD, et al. Discovery of gene function by
expression profiling of the malaria parasite life cycle. Science. 2003; 301(5639):1503–8. https://doi.org/
10.1126/science.1087025 PMID: 12893887
77. Zhang VM, Chavchich M, Waters NC. Targeting protein kinases in the malaria parasite: update of
an antimalarial drug target. Curr Top Med Chem. 2012; 12(5):456–72. Epub 2012/01/17. PMID:
22242850
78. Doerig C, Abdi A, Bland N, Eschenlauer S, Dorin-Semblat D, Fennell C, et al. Malaria: targeting parasite
and host cell kinomes. Biochim Biophys Acta. 2010; 1804(3):604–12. Epub 2009/10/21. https://doi.org/
10.1016/j.bbapap.2009.10.009 PMID: 19840874
79. Doerig C, Meijer L. Antimalarial drug discovery: targeting protein kinases. Expert Opin Ther Targets.
2007; 11(3):279–90. Epub 2007/02/15. https://doi.org/10.1517/14728222.11.3.279 PMID: 17298288
80. Jacot D, Tosetti N, Pires I, Stock J, Graindorge A, Hung YF, et al. An Apicomplexan Actin-Binding Pro-
tein Serves as a Connector and Lipid Sensor to Coordinate Motility and Invasion. Cell Host Microbe.
2016; 20(6):731–43. https://doi.org/10.1016/j.chom.2016.10.020 PMID: 27978434
81. Bargieri DY, Andenmatten N, Lagal V, Thiberge S, Whitelaw JA, Tardieux I, et al. Apical membrane anti-
gen 1 mediates apicomplexan parasite attachment but is dispensable for host cell invasion. Nat Com-
mun. 2013; 4:2552. https://doi.org/10.1038/ncomms3552 PMID: 24108241
82. Treeck M, Zacherl S, Herrmann S, Cabrera A, Kono M, Struck NS, et al. Functional analysis of the lead-
ing malaria vaccine candidate AMA-1 reveals an essential role for the cytoplasmic domain in the inva-
sion process. PLoS Pathog. 2009; 5(3):e1000322. https://doi.org/10.1371/journal.ppat.1000322 PMID:
19283086
83. Harupa A, Sack BK, Lakshmanan V, Arang N, Douglass AN, Oliver BG, et al. SSP3 is a novel Plasmo-
dium yoelii sporozoite surface protein with a role in gliding motility. Infect Immun. 2014; 82(11):4643–
53. Epub 2014/08/27. https://doi.org/10.1128/IAI.01800-14 PMID: 25156733
84. Song G, Springer TA. Structures of the Toxoplasma gliding motility adhesin. Proc Natl Acad Sci
U S A. 2014; 111(13):4862–7. Epub 2014/03/19. https://doi.org/10.1073/pnas.1403059111 PMID:
24639528
85. Luca VC, Jude KM, Pierce NW, Nachury MV, Fischer S, Garcia KC. Structural biology. Structural basis
for Notch1 engagement of Delta-like 4. Science. 2015; 347(6224):847–53. Epub 2015/02/24. PMID:
25700513
86. Arredondo SA, Cai M, Takayama Y, MacDonald NJ, Anderson DE, Aravind L, et al. Structure of the
Plasmodium 6-cysteine s48/45 domain. Proc Natl Acad Sci U S A. 2012; 109(17):6692–7. https://doi.
org/10.1073/pnas.1204363109 PMID: 22493233
87. Zhang Y, Liu R, Ni M, Gill P, Lee AS. Cell surface relocalization of the endoplasmic reticulum chaperone
and unfolded protein response regulator GRP78/BiP. J Biol Chem. 2010; 285(20):15065–75. https://
doi.org/10.1074/jbc.M109.087445 PMID: 20208072
Proteogenomic analysis of Plasmodium vivax salivary gland sporozoites
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005791 July 31, 2017 35 / 36
88. Montagna GN, Buscaglia CA, Munter S, Goosmann C, Frischknecht F, Brinkmann V, et al. Critical role
for heat shock protein 20 (HSP20) in migration of malarial sporozoites. J Biol Chem. 2012; 287
(4):2410–22. Epub 2011/12/06. https://doi.org/10.1074/jbc.M111.302109 PMID: 22139844
89. Simon N, Lasonder E, Scheuermayer M, Kuehn A, Tews S, Fischer R, et al. Malaria parasites co-opt
human factor H to prevent complement-mediated lysis in the mosquito midgut. Cell Host Microbe. 2013;
13(1):29–41. https://doi.org/10.1016/j.chom.2012.11.013 PMID: 23332154
Proteogenomic analysis of Plasmodium vivax salivary gland sporozoites
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005791 July 31, 2017 36 / 36
